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Kelly E. Craven
ANGIOGENIC GENE SIGNATURE IN HUMAN PANCREATIC CANCER
CORRELATES WITH TGF-BETA AND INFLAMMATORY TRANSCRIPTOMES
Pancreatic ductal adenocarcinoma (PDAC), which comprises 85% of pancreatic
cancers, is the 4th leading cause of cancer death in the United States with a 5-year
survival rate of 8%. While human PDACs (hPDACs) are hypovascular, they also
overexpress a number of angiogenic growth factors and receptors. Additionally, the use
of anti-angiogenic agents in murine models of PDAC leads to reduced tumor volume,
tumor spread, and microvessel density (MVD), and improved survival. Nonetheless,
clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful in
hPDAC. On the other hand, pancreatic neuroendocrine tumors (PNETs) account for
only 2% of pancreatic tumors, yet they are very vascular and classically angiogenic,
respond to anti-angiogenic therapy, and confer a better prognosis than PDAC even in
the metastatic setting.
In an effort to compare and contrast the angiogenic transcriptomes of these
two tumor types, we analyzed RNA-Sequencing (RNA-Seq) data from The Cancer
Genome Atlas (TCGA) and found that a pro-angiogenic gene signature is present in
35% of PDACs and that it is mostly distinct from the angiogenic signature present in
PNETs. The pro-angiogenic PDAC subgroup also exhibits a transcriptome that reflects
active TGF-β signaling, less frequent SMAD4 inactivation than PDACs without the
signature, and up-regulation of several pro-inflammatory genes, including members
of JAK signaling pathways. Consequently, targeting the TGF-β receptor type-1
kinase with SB505124 and JAK1/2 with ruxolitinib blocks proliferative crosstalk
between human pancreatic cancer cells (PCCs) and human endothelial cells (ECs).
Additionally, treatment of the KRC (oncogenic Kras, homozygous deletion of Rb1) and
KPC (oncogenic Kras, mutated Trp53) genetically engineered PDAC mouse models
with ruxolitinib suppresses murine PDAC (mPDAC) progression only in the KRC
model, which shows superior enrichment and differential expression of the human
pro-angiogenic gene signature as compared to KPC tumors. These findings suggest
that targeting both TGF-β and JAK signaling in the 35% of PDAC patients whose
cancers exhibit an pro-angiogenic gene signature should be explored in a clinical trial.
Murray Korc, MD, Chair
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1 Introduction
1.1 Pancreas
The pancreas is located dorsally to the stomach at the L2 vertebral level in the
upper abdomen (Figure 1.1). It is a retroperitoneal organ that sits in the “C” loop of
the duodenum and slopes upwards towards the splenic hilum (Figure 1.1) [1, 2]. It
functions both as an exocrine organ to support digestion and as an endocrine organ to
control blood glucose levels [1–5]. The exocrine parenchyma, acini and ducts, makes
up ∼85% of the pancreas while the endocrine parenchyma, the islets of Langerhans,
constitute only 1-2% of the pancreas [1].
Figure 1.1: Pancreas. The main anatomical structures of the pancreas. The hepatopancreatic
ampulla is also known as the ampulla of Vater. The micrographs highlight a pancreatic islet and
acinus. Image reproduced from [5].
1.2 Exocrine pancreas
The exocrine pancreas is a secretory organ that secretes a pancreatic juice rich in
HCO3
- and digestive enzymes into a ductal system leading to the duodenum to help
neutralize and digest the gastric contents being emptied from the stomach [4]. The
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secretory unit of the pancreas consists of an acinus made up of 15 to 100 acinar cells
that secrete digestive zymogens into an intercalated duct (Figure 1.2A) [4]. Multiple
acini make up a larger unit called a lobule, and the intercalated ducts of the lobule
drain into an intralobular duct, and the intralobular ducts from different lobules then
drain into an interlobular duct (Figure 1.2B) [4]. The interlobular ducts drain into
the main pancreatic duct, and this duct joins with the common bile duct immediately
proximal to the duodenum to form the ampulla of Vater (Figure 1.1) [4]. This ampulla
then drains bile and pancreatic juice via the greater duodenal papilla (also known
as the major duodenal papilla) into the duodenum (Figure 1.1) [4]. There is also an
accessory pancreatic duct that fuses with the main pancreatic duct during development
and drains separately into the duodenum through the lesser duodenal papilla (Figure
1.1), though it can also end blindly in the pancreas in 30% of patients [2]. In an even
a smaller percentage of patients (10%), these ducts fail to fuse, and the majority of
the pancreas is then drained through the lesser duodenal papilla [2].
A
B
Figure 1.2: Acinar and ductal morphology of the pancreas. (A) The basic secretory unit
of the pancreas consists of many acinar cells surrounding an intercalated duct. Acinar cells are
specialized secretory cells with many zymogen granules present on their apical side posed for release
into the duct upon neurohumoral stimulation by cholecystokinin (CCK) or the neurotransmitter
acetylcholine. Image reproduced from [5]. (B) Intercalated ducts within a lobule of acini will coalesce
into a larger intralobular duct and multiple intralobular ducts come together to form an interlobular
duct. Interlobular ducts then drain into the main pancreatic duct. Image reproduced from [4].
Acinar cells are polarized epithelial cells that synthesize digestive enzymes that
are packaged into zymogen granules on the apical side facing the duct lumen (Figure
1.2A) [4]. When lipid and protein digestive products enter the duodenum from the
stomach, they stimulate the release of cholecystokinin (CCK) from I cells in the
duodenal mucosa, and they stimulate afferent pathways that initiate a vagovagal reflex
[4]. CCK will circulate and bind to CCK receptors on acinar cells to stimulate the
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secretion of the zymogen granules’ contents into the pancreatic ductal system [4].
Postganglionic parasympathetic neurons in the pancreas also release acetylcholine and
exert the same effect through muscarinic cholinergic receptors on the acinar cells [4].
In a similar manner, gastric acid in the duodenum will stimulate duodenal S cells to
release secretin (gene: SCT), and secretin will circulate and then act on the ductal
cells to stimulate the secretion of HCO3
- rich fluid into the ducts [4].
1.3 Endocrine pancreas
The normal human pancreas contains 500,000 to several million islets of Langerhans
[6]. Islets are oval or spherical in shape and contain four types of secretory cells, α, β,
δ, and F cells (Figure 1.3) [6]. α cells secrete glucagon (gene: GCG), β cells secrete
insulin (gene: INS), δ cells secrete somatostatin (gene: SST), and F cells secrete
pancreatic polypeptide (gene: PPY) (Figure 1.3) [6]. Insulin stimulates target tissues
like the liver, muscle, and adipose tissue to take up carbohydrates, lipids, and amino
acids during the fed state [6]. Insulin maintains glucose levels in the plasma within
narrow limits, and both hypo- or hyperglycemia can produce characteristic symptoms
in patients [6]. The hallmark of the diabetic state is hyperglycemia, and diabetes can
be caused either by destruction of the β cells via immune mediated mechanisms (type
1 diabetes) or by impaired insulin secretion and tissue response (type 2 diabetes) [6].
Insulin release is triggered by glucose, neural, or incretin stimulation of the β cells [6].
Glucagon release is stimulated by protein ingestion and its main actions are to
regulate carbohydrate and lipid metabolism in the liver [6]. In many respects, it
antagonizes the actions of insulin by stimulating glycogenolysis, gluconeogenesis, and
ketogenesis in the liver [6]. In contrast, insulin promotes glycogen synthesis, glycolysis,
and the synthesis of fats in the liver. While somewhat confounding, glucagon would
prevent hypoglycemia during ingestion of a protein rich meal without a carbohydrate.
Its role in the production of glucose and ketone bodies is also important in the fasting
state when insulin is low [6]. During fasting, the brain can utilize ketone bodies but
not fatty acids as fuel [6].
Somatostatin inhibits the growth of many different types of hormones, including
growth hormone, insulin, glucagon, gastrin (gene: GAST), vasoactive intestinal peptide
(gene: VIP) (VIP), and thyroid-stimulating hormone [6]. Pancreatic polypeptide has
unknown functions in mammalian metabolism [6].
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Figure 1.3: Islet of Langerhan. Pancreatic islets contain four types of secretory cells, α, β, δ,
and F cells, that secrete insulin (gene: INS), glucagon (gene: GCG), somatostatin (gene: SST), and
pancreatic polypeptide (gene: PPY) into the bloodstream, respectively. Image reproduced from [6].
1.4 Angiogenesis
Blood vessel growth throughout adult life is primarily achieved via angiogenesis
[7–13]. However, the adult vasculature is mostly quiescent as only 0.01% of the
endothelium undergoes cell division at any time [7, 8, 10, 12, 13]. Examples of
physiologic angiogenesis in the adult include wound healing, tissues undergoing growth,
exercise induced angiogenesis in heart and skeletal muscle, the hair cycle, skeletal
growth, and female reproductive processes. Pathologic examples include intraocular
neovascular disorders, infantile haemangiomas, immunogenic rheumatoid arthritis,
psoriasis, and tumorigenesis [7, 8, 11–15].
Through the use of models like the mouse retina, which becomes vascularized
postnatally, we now understand many of the key players and processes involved in
physiologic angiogenesis [16]. In general, activation of endothelial cells (ECs) by
pro-angiogenic molecules leads to the detachment of pericytes from the endothelium
and remodeling of the basement membrane and cell-to-cell junctions (Figure 1.4)
[17]. The best known pro-angiogenic molecule is VEGF-A (gene: VEGFA). VEGF-A
binds to VEGFR-2 (gene: KDR) on ECs, and its signaling is enhanced by the NRP1
co-receptor, which facilitates complex internalization (Figure 1.4) [17]. Downstream
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signaling results in increased expression of the NOTCH ligand DLL4, which binds
to NOTCH receptors on neighboring ECs (Figure 1.4) [17]. This releases the notch
intracellular domain (NICD) in these cells, which down-regulates VEGFR-2 and NRP1,
and up-regulates VEGFR-1 (gene: FLT1), a decoy receptor for VEGF-A (Figure 1.4)
[17].
The goal of this process is to isolate one cell that will migrate toward the pro-
angiogenic gradient (called the tip cell), while de-sensitizing neighboring cells to
the same signal. It is believed that DLL4 and NOTCH signaling are balanced in
the quiescent vasculature, and that tip cells will offset the balance in response to
pro-angiogenic signals [9]. The cells adjacent to the tip cell are called stalk cells, and
they proliferate behind the tip cell to elongate the sprout and form a lumen (Figure
1.4) [17]. Once two tip cells on different sprouts meet, they will anastomose to form a
perfused branch (Figure 1.4) [17]. Basement membrane then forms, and pericytes are
recruited to cover the vessel (Figure 1.4) [17]. The process is dynamic in that ECs will
compete for the tip position with different cells displaying the phenotype over time.
1.5 Tumor angiogenesis
Whereas physiologic angiogenesis is tightly controlled and comes to a resolution,
pathologic angiogenesis is abnormal and does not resolve [8, 11, 12, 15, 16]. Because
cells need nutrients and oxygen from nearby capillaries to function and survive, early
tumor growth is often restricted to a volume of only a few cubic millimeters until the
tumor is able to switch to an angiogenic phenotype [8, 11, 12, 14, 15, 18, 19]. Activation
of angiogenesis occurs when pro-angiogenic molecules predominate over anti-angiogenic
molecules, whereas, inactivation occurs when the anti-angiogenic molecules dominate
[7, 8, 20]. In tumorigenesis, the observed activation from a quiescent state is often
described as an “angiogenic switch” [7, 8, 20].
The vessels formed during tumor angiogenesis are tortuous or disorganized, im-
mature, and convoluted with excessive vessel branching that lacks pericyte coverage
rendering them fragile and leaky with bleeding and exudation of plasma proteins [10–
13, 16, 17, 19, 21]. The distribution of new vessels in the tumor is also heterogeneous
with some areas demonstrating intense neovascularization [10, 14, 15, 17, 21]. The
vessels are often functionally defective with low blood flow and reduced oxygen delivery
due to high interstitial pressure [10, 13, 17, 21]. The resulting hypoxic environment
exacerbates the pathologic condition by further up-regulating pro-angiogenic molecules
[10, 17, 21]. While one might assume that neovascularization would improve delivery
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Figure 1.4: Pancreatic ductal adenocarcinoma (PDAC) angiogenesis. In PDAC, pancreatic
cancer cells (PCCs) proliferate within a desmoplastic stroma that consists of both cellular components
such as cancer associated fibroblasts (CAFs), immune cells (Is), and endothelial cells (ECs) as well as
extracellular matrix (ECM) components like soluble growth factors, cytokines, collagens, fibronectin,
laminin, glycoproteins, and proteoglycans.
Up-regulation of HIF-1α (gene: HIF1A) and the pro-angiogenic molecule VEGF-A (gene: VEGFA)
within PCCs results in secretion of VEGF-A molecules into the tumor microenvironment. When
VEGF-A signals through VEGFR-2 (gene: KDR) and its NRP1 co-receptor on ECs, downstream
signaling results in increased expression of DLL4. DLL4 will bind to NOTCH receptors on neighboring
cells, subsequently releasing notch intracellular domain (NICD), which then down-regulates VEGFR-2
and NRP1 expression and up-regulates expression of the VEGFR-1 (gene: FLT1) decoy receptor.
This favors migration of a tip cell towards the VEGF-A gradient while the neighboring stalk cells
become de-sensitized to the signal. In the quiescent vasculature, DLL4 and NOTCH signaling are
balanced.
Small molecule inhibitors of angiogenesis, such as Axitinib, Sunitinib, Sorafenib, and Vatalanib
primarily act on the vascular endothelial growth factor receptor (VEGFR) complexes (VEGFR-1,
VEGFR-2, and VEGFR-3 (gene: FLT4)) while recombinant protein inhibitors of angiogenesis like
Bevacizumab, Elpamotide, and Ziv-Aflibercept act on VEGF ligands like VEGF-A, VEGF-B (gene:
VEGFB), and/or PlGF (gene: PGF).
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of chemotherapeutic agents to the tumor, the poor perfusion and compression of
the vascular supply actually impedes drug delivery [10, 11, 13, 15, 17]. Therefore,
in addition to inhibiting angiogenesis and causing vessel regression, anti-angiogenic
agents can enhance the effects of simultaneously administered chemotherapeutic drugs
by normalizing the remaining vasculature [10, 11, 13, 15–17, 21].
1.6 Pancreatic ductal adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is a pancreatic tumor which arises
from the exocrine pancreas and comprises >85% of pancreatic cancers [22–24]. PDAC
is the 4th leading cause of cancer death in the United States with a 5-year relative
survival rate of 8% [22–24]. These statistics are largely due to advanced stage at
clinical presentation, a high frequency of major driver mutations, marked resistance to
chemotherapy and radiation, and extensive desmoplasia that impedes drug delivery [25–
29]. Because advances in screening, prevention, and treatment are limited compared
to other cancers, PDAC is now projected to surpass breast, prostate, and colorectal
cancers to become the second leading cause of cancer death by 2030 [30].
At presentation, only 15–20% of patients are eligible for surgical resection, the
only chance for cure [22, 31, 32]. Even then, outcomes are poor, with a 5 year
survival between 20–25% post-resection, since most of these patients develop disease
recurrence [33]. Therefore, chemotherapy is recommended as adjuvant treatment for
those undergoing surgical resection and is the mainstay of treatment for patients with
locally advanced or metastatic disease [31]. The current standard of care for patients
with metastatic disease includes gemcitabine plus nab-paclitaxel or fluorouracil plus
leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) [31, 34].
1.7 PDAC is hypovascular
Using the KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre (KPC) PDAC mouse
model, which has oncogenic Kras and mutated Trp53 in the pancreas due to Cre-
mediated recombination, Olive et al. showed that KPC tumors are poorly vascularized,
poorly perfused, and have impaired drug delivery when compared to KPC transplant
models or normal mouse pancreas [35]. Likewise, using both KrasLSL-G12D/+; Pdx-
1-Cre (KC) mice, which have oncogenic Kras in the pancreas due to Cre-mediated
recombination, and KPC mice, Provenzano et al. reported that in addition to having
reduced vascularity, KC and KPC tumors have a paucity of large diameter (>10
um) vessels when compared to normal mouse pancreas [36]. This is likely due to
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vascular collapse caused by the presence of very high interstitial fluid pressures in
these tumors, in the range of 75–130 mm Hg, compared to 8–13 mm Hg in normal
mouse pancreas [36]. This observation also offers an explanation for the poor perfusion
and drug delivery observed by Olive et al. [35]. Human PDAC (hPDAC) samples
were also shown to be poorly vascularized compared to normal human pancreas or
adjacent normal human pancreas, and to have fewer large diameter vessels compared
to adjacent normal human pancreas [35, 36].
Because PDAC is inherently hypovascular, it might be assumed that this cancer
either does not demonstrate significant angiogenesis or that it is not likely to benefit
from anti-angiogenic agents. However, both concepts have been disproven in other
cancers [37]. All tumor types need sufficient levels of nutrients and oxygen and are
growth limited unless they are able to induce angiogenesis. This is also true of hypoxic
tumors, which likely have increased requirements to drain away toxic by-products
released by cancer cells. Instead of measuring angiogenesis, microvessel density (MVD)
rather reflects the metabolic burden of the supported tumor cells [37]. In fact, because
the oxygen consumption rate is often lower in tumors compared to the corresponding
normal tissue, it is not uncommon for tumors to have lower MVDs as we see in PDAC
[37]. This is also the case for renal cell carcinoma, a cancer known clinically to respond
to anti-angiogenic therapy [37]. Both poorly and highly vascularized cancers have
been shown to respond to anti-angiogenic therapy [37].
1.8 Correlation of VEGF-A expression or microvessel density (MVD)
with health outcomes in PDAC
VEGF-A, a potent inducer of angiogenesis, was first discovered as a secreted protein
that can enhance vascular permeability [7]. Many different isoforms exist, and their
different binding affinities for heparan sulfate proteogylycans (HSPGs) function to
create a gradient for guiding vessels during vascular development [11]. In recent years,
more insight into the alternative splicing and translation of the gene has revealed that
anti-angiogenic forms and a translational read through can also be produced [38, 39].
Using immunohistochemistry (IHC), several groups found that between 60–65%
of hPDAC samples have a substantial amount of VEGF-A immunoreactivity [40–42].
In terms of gene expression, Ikeda et al. found that 27/40 (67.5%) hPDAC samples
overexpress VEGFA compared to a colon cancer cell line while Itakura et al. found a
5.2 fold increase in VEGFA expression in hPDAC samples (n=7) compared to normal
human pancreas samples (n=4) [40, 42].
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MVD has not been shown to be an accurate measure of angiogenesis in other cancers
[37]; nonetheless, three [40–42] of four [43] studies of hPDAC samples have shown an
association between VEGFA mRNA or VEGF-A protein (IHC) expression and the
amount of vascularity seen in the tumor. Patients with high levels of VEGFA mRNA
or VEGF-A protein (IHC) also had increased liver metastasis [41], larger tumors [42],
enhanced local spread [42], and decreased survival in two [40, 41] out of four [42, 43]
studies. Lastly, one [40] out of two [43] studies reported that increased vascularity
was associated with decreased patient survival. More recently, by RNA-Sequencing
(RNA-Seq), The Cancer Genome Atlas (TCGA) dataset shows that only 8 out of 178
(4%) hPDAC samples overexpress VEGFA (2 z-scores above the mean, according to
criteria established by Memorial Sloan Kettering Cancer Center), suggesting that this
molecule may not be as important in PDAC as was first surmised [29, 44, 45].
1.9 Pre-clinical studies targeting VEGF signaling in PDAC
Many studies have examined the potential role of targeting VEGF signaling using
subcutaneous or orthotopic nude mouse models of hPDAC. Injection of hPDAC cells
expressing an anti-sense VEGFA into the flanks of nude mice led to an 80% reduction
in tumor size compared to controls [46]. When diphtheria toxin, which inhibits protein
synthesis in target cells, was fused with VEGF-A to target it to the vasculature in
orthotopic nude mouse models of hPDAC, it led to reduced tumor volume, tumor
spread, and MVD, and improvement in survival in 1 of 2 models [47]. Injection of
adenovirus vectors encoding the soluble form of the decoy receptor VEGFR-1 into
subcutaneous tumor xenografts of hPDAC in severe combined immunodeficiency
(SCID) mice also resulted in reduced tumor growth and MVD [48]. Additionally,
injection of adenovirus vectors encoding soluble VEGFR-1 or soluble VEGFR-1 plus
a soluble FGFR-1 (gene: FGFR1) into subcutaneous tumor xenografts of hPDAC in
nude mice resulted in reduced tumor growth [49].
The tyrosine kinase inhibitor PTK 787/ZK222584 (vatalanib) targets vascular
endothelial growth factor receptors (VEGFRs), the platelet-derived growth factor
receptors (PDGFRs), SCFR (gene: KIT), and CSF1R. Use of this compound in an
orthotopic nude mouse model of hPDAC led to reduced tumor volume and MVD,
and increased survival [50]. Moreover, use of VEGF-Trap (ziv-aflibercept), which is a
recombinant fusion protein of the extracellular portions of VEGFR-1 and VEGFR-2
and the Fc fragment of human immunoglobulin IgG1, resulted in reduced tumor
growth and MVD in subcutaneous tumor xenografts of hPDAC and reduced tumor
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growth and metastasis in an orthotopic nude mouse model of hPDAC [51]. These
promising results provide support for the testing of anti-VEGF agents in hPDAC
clinical trials.
1.10 Clinical studies using anti-angiogenic agents in PDAC
To date, many phase II and phase III hPDAC clinical trials using different anti-
angiogenic agents have been completed. Several of these involved bevacizumab, an anti-
VEGF-A monoclonal antibody, that has already been FDA approved for the treatment
of several other cancer types, including persistent, recurrent, or metastatic cervical
cancer, metastatic colorectal cancer, or non-small cell lung cancer in combination with
chemotherapy; metastatic renal cell carcinoma in combination with interferon alpha;
or in glioblastoma as a second-line therapy.
An initial Phase II trial of bevacizumab plus gemcitabine in untreated advanced
PDAC patients showed a 21% objective response rate (ORR), a 6-month survival rate
of 77%, and a median survival of 8.8 months (Table 1.1) [52]. Because these were
favorable numbers compared to the pivotal trial for gemcitabine approval [53], which
observed an ORR of 5%, a 6-month survival rate of 46%, and a median survival of 5.7
months, several other Phase II and Phase III studies were launched.
Several Phase II trials added bevacizumab to any existing regimen that had previ-
ously shown any sort of modest activity in PDAC. These regimens included: cisplatin
and gemcitabine [54]; capecitabine and gemcitabine [55]; capecitabine, radiation, and
gemcitabine [56]; oxaliplatin and gemcitabine [57]; gemcitabine and radiation [58, 59],
and docetaxel [60] (Table 1.1). However, results from the Phase III trial directly com-
paring bevacizumab plus gemcitabine to placebo plus gemcitabine in advanced PDAC
patients showed that the addition of bevacizumab does not result in an improvement
in overall survival (OS) or progression free survival (PFS) or differences in the ORR
(Table 1.2) [61].
The difference between the Phase II and Phase III results was suggested to be due
to the Phase II trial recruiting a more fit population [61]. Because such disparities
are common in trials of PDAC, it was also suggested that the use of a single-arm
Phase II trial is not ideal [61]. The majority of Phase II trials with other regimens
were single-arm trials, and thus, most of them also concluded that the addition of
bevacizumab produced questionable benefit.
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In addition to VEGF-A, EGFR and its ligands are commonly overexpressed in
hPDAC, and high expression levels are also associated with worse outcomes [62–65].
The addition of cetuximab, a monocloncal antibody targeting EGFR, to gemcitabine
has not led to improvements in ORRs, PFS, or OS [66], but the addition of erlotinib,
a small molecule inhibitor of EGFR, to gemcitabine has been shown to provide a
statistically significant improvement in survival [67]. However, the clinical relevance
of this result is often questioned since the median gain in survival is only 10 days [67].
There is also evidence for EGFR’s role in angiogenesis and simultaneous inhibition
of EGFR and VEGFR-2 has been shown to be synergistic [62, 64, 80–82]. Therefore,
several regimens combining cetuximab or erlotinib with bevacizumab have been tried
with limited success (Table 1.3) [83–85]. A Phase III trial comparing bevacizumab
plus erlotinib plus gemcitabine to placebo plus erlotinib plus gemcitabine in metastatic
PDAC patients did not show benefit in OS, but it did show a statistically significant
one month improvement in the median PFS (Table 1.2) [75]. Therefore, there is some
rationale for using this drug combination in metastatic PDAC patients.
Additional anti-angiogenic agents that have been tried in hPDAC include axitinib,
sunitinib, sorafenib, vatalanib, ziv-aflibercept, and elpamotide. The Phase II or III
trial comparing axitinib, a VEGFR tyrosine kinase inhibitor, plus gemcitabine to
gemcitabine alone did not provide a significant improvement in overall or PFS (Table
1.1, 1.2) [68, 76].
Sunitinib is a small molecule tyrosine kinase inhibitor of VEGFRs, PDGFRs, and
SCFR. Though a Phase III study has not been done, this molecule has been tested in
the metastatic setting as either a second-line therapy [69] or as a maintenance therapy
in patients who did not progress after first-line chemotherapy [70]. Interestingly, in
these patient groups, the drug did not do well as a second-line therapy (Table 1.1),
but produced a statistically significant improvement in PFS compared to observation
alone in the maintenance setting (Hazard Ratio (HR) 0.51 [95% confidence interval
(CI): 0.29–0.89], p-value < 0.01) [70]. Because the duration of first-line chemotherapy
is often debated due to its cumulative toxicity and unproven efficacy, sunitinib may
offer an advantage in the maintenance setting.
Similarly, sorafenib is a small molecule tyrosine kinase inhibitor of BRAF, VEGFRs,
and PDGFRB that has been tested in many different settings without benefit (Table 1.1,
1.3) [71–73, 86]. These observations were confirmed in a Phase III trial that observed
no improvement in overall or PFS upon the addition of sorafenib to gemcitabine in
the treatment of advanced PDAC patients (Table 1.2) [77].
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Vatalanib is also a multi-kinase inhibitor targeting VEGFRs, PDGFRs, SCFR,
and CSF1R. In a Phase II trial, it was used as a second-line therapy in advanced
PDAC patients and produced a favorable 6 month survival rate of 29% compared to
historic controls (Table 1.1) [74]. However, it was only a single-arm trial, and with
the failure of several other similar receptor tyrosine kinase inhibitors, it remains to be
seen whether this drug will pan out.
Ziv-aflibercept, a recombinant fusion protein consisting of the extracellular portions
of VEGFR-1 and VEGFR-2 and the Fc fragment of human immunoglobulin IgG1, is
another drug that targets the VEGF pathway by trapping VEGF-A, VEGF-B, and
PlGF (gene: PGF). This drug yielded negative results in a Phase III trial compared
to gemcitabine alone (Table 1.2) [78].
Elpamotide, a VEGFR-2 peptide, is a vaccine immunotherapy that can induce
a cellular immune response against VEGFR-2 expressing ECs [79, 87]. In a Phase
II/III trial (Table 1.2) of locally advanced or metastatic pancreatic cancer patients,
there were no improvements in overall or PFS compared to gemcitabine alone, but a
subgroup with severe injection site reactions tended to do better, suggesting that this
may be a sign of immune response to the vaccine [79].
Thus, targeting the VEGF pathway alone is not an efficacious route in PDAC.
Even targeting multiple players in the neoplastic process, like EGFR or other re-
ceptor tyrosine kinases, produced marginal benefit, with only two trials showing an
improvement in PFS, but not OS [70, 75].
1.11 Pancreatic neuroendocrine tumor (PNET)
Pancreatic neuroendocrine tumors (PNETs) are tumors that arise from the en-
docrine pancreas and comprise only 1–4% of pancreatic tumors [88, 89]. They are
associated with a better prognosis than PDAC with a 5 year survival rate of 53%
[24]. PNETs represent a spectrum of different diseases that range from indolent,
well-differentiated, and low-grade to aggressive, poorly differentiated, and high-grade
tumors [88]. They can also be classified as being functional or nonfunctional depending
on whether they secrete a hormone that manifests in clinical symptoms [88, 89]. Usu-
ally 70–75% are nonfunctional [88, 89]. Possible hormones include gastrin, insulin, VIP,
glucagon, somatostatin, growth hormone releasing hormone (gene: GHRH) (GHRH),
and adrenocorticotropic hormone (gene: POMC) (ACTH) resulting in tumors called
gastrinomas, insulinomas, VIPomas, glucagonomas, somatostatinomas, GRFomas, and
ACTHomas, respectively [89]. Nonfunctional PNETs can also secrete peptides that
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don’t produce a clinical syndrome [89]. Some PNETs are caused by familial syndromes,
including multiple endocrine neoplasia type-1 (MEN-1), von Hippel-Lindau disease,
neurofibromatosis 1, and tuberous sclerosis [88, 89], but their clinical presentation,
prognosis, and management differ from sporadic PNETs [89]. Usually 60–70% of
patients have metastatic disease at presentation and except for insulinomas, malignant
characteristics are present in at least 50% of cases [89]. Insulinomas are the most com-
mon type of functional PNET, and fewer than 10% are malignant [89]. Gastrinomas
are the second most common type of functional PNET and though 60% demonstrate
malignant behavior, the 10 year survival rate approaches 90% even with metastatic
disease [89].
Therapy options for PNETs include surgery, somatostatin analogues, cytotoxic
chemotherapy, and targeted agents [88]. Approximately, 80% of PNETs express so-
matostatin receptors (SSTRs) (usually SSTR2), and therefore, somatostatin analogues
can improve hormone secretion symptoms in many patients, especially in those with
VIPomas and glucagonomas [88]. Proton pump inhibitors are usually used to control
the excess gastric acid production seen in gastrinomas [88]. Exome sequencing studies
of sporadic PNETs have found that the most frequently mutated genes are involved in
chromatin remodeling, including MEN1, DAXX, and ATRX, or the mTOR pathway
[88]. Indeed, 14% of tumors have mutations in the mTOR pathway, and everolimus
has been approved by the Food and Drug Administration (FDA) for patients with
progressive PNETs [88].
Early studies using cytotoxic chemotherapy in PNETs have demonstrated response
rates often higher than what is seen with somatostatin analogues or targeted agents.
Accordingly, cytotoxic agents are often used in patients with more progressive disease
[88]. Trials to date have observed response rates that range from 8% to 70% with the
use of drugs like streptozocin plus doxorubicin, dacarbazine, temozolomide, or temo-
zolomide in combination with thalidomide, bevacizumab, everolimus, or capecitabine
[88].
Clinically, PNETs are vascular tumors and express VEGF proteins, including
VEGF-A and VEGFR-2 [88]. Additionally, a Phase III trial using sunitinib demon-
strated an improvement in PFS, 11.4 months vs. 5.5 months for placebo (HR 0.42
[0.26-0.66]), with a tumor response rate of 9% vs. 0%. Sunitinib is now FDA approved
for the treatment of progressive PNETs. Additional agents tried in Phase II studies in-
clude sorafenib, pazopanib, and bevacizumab, with tumor response rates from 9%–22%
[88]. There have also been Phase II trials that have combined an mTOR inhibitor with
bevacizumab, and these trials have demonstrated higher levels of response compared
18
to single agent therapy [88]. Temsirolimus with bevacizumab has produced a 41%
response rate and a 13.2 month PFS [88]. Everolimus with bevacizumab has produced
a 31% response rate and a 16.7 month PFS while everolimus alone produced a 12%
response rate and a 14 month PFS (response rate P-value (P)=0.005; PFS HR 0.80
[0.55–1.17], P=0.12) [88]. Overall, surgical resection is the main treatment modality for
localized disease, and this along with systemic therapy options including somatostatin
analogues, targeted agents, and cytotoxic chemotherapy can be used in advanced
disease [88].
1.12 Need for better understanding of angiogenesis in pancreatic cancer
The overwhelming failure of anti-angiogenic agents in PDAC in the clinic leads
us to speculate on the reasons for its failure and why other tumor types like PNETs
respond. As is often observed in many clinical trials, patient responses are variable,
with only a subset of patients benefiting from the therapy, while overall, no positive
effect may be seen. Even in the PNET trials, not all patients responded. It would
be useful if we could identify those patients who might benefit the most via the
use of predictive biomarkers. Though some PDAC trials have attempted to look
for correlations between certain known pro-angiogenic molecules circulating in the
plasma and treatment response, none have been successful to date [52, 54, 60, 74].
With an increasing number of studies utilizing high throughput technologies like
RNA-Seq to profile human tumors, it is possible that a gene expression signature
could be used. Therefore, we utilized RNA-Seq data from TCGA to identify novel
angiogenic genes and pathways important in subsets of PDAC tumors. While two
studies have already utilized transcriptomics to highlight the presence of different
PDAC subgroups [90, 91], both studies focused on the whole transcriptome, and only
one study attempted to identify corresponding PDAC cell lines representative of that
subgroup for testing responses to targeted therapies designed specifically for that
subgroup [90]. For the first time, by doing a focused analysis on the expression of
angiogenic genes in PDAC tumors, we have identified angiogenesis specific subgroups
in hPDAC. We also identified Genetically Engineered Mouse Models (GEMMs) of
PDAC that are representative of these subgroups, and we have tested responses to
therapy targeting subgroup specific pathways in these models.
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2 Results
2.1 Vascularity is heterogeneous among PDAC tumors
To investigate the vascularity of hPDAC tumors, we performed staining of the
endothelial specific marker CD31 (gene: PECAM1) in 54 tumors and found that
28% (15/54) of tumors had strong staining (Figure S1), 37% (20/54) had moderate
staining (Figure S2), and 35% (19/54) had weak staining (Figure S3) (Figure 2.1A-B).
This suggests that while PDAC is hypovascular compared to the normal pancreas,
significant heterogeneity still exists between PDAC tumors.
2.2 Identification of a pro-angiogenic gene signature
Because of the failure of anti-VEGF therapy in PDAC clinical trials, we sought
to determine if other angiogenic genes or pathways might be important in subsets of
PDAC patients. To do this, we decided to use RNA-Seq gene expression information
from TCGA. In June of 2014, TCGA contained RNA-Seq gene expression information
on 85 pancreatic cancer tumors: 76 PDAC, 3 colloid (mucinous non-cystic) carcinomas,
and 6 of an unknown type. One approach to this problem would be to first label
samples as to whether they have an angiogenic phenotype or not, and then use
supervised machine learning methods on the gene expression data to identify subsets
of genes that can differentiate between the two types [92, 93]. However, because
all tumors require angiogenesis to grow, we can’t label samples based on whether
angiogenesis is occurring or not, but we could use phenotypes that score the amount
of angiogenesis or the MVD of the tumor. Unfortunately, TCGA does not provide a
way to score angiogenesis in the tumors, which might be obtained by quantifying the
amount of proliferating ECs in the tumors. CD31 protein expression is available from
a reverse phase protein array (RPPA), but as has been mentioned previously, it is not
clear whether MVD is a good measure of angiogenesis [37].
Therefore, our real question is whether certain angiogenic genes or pathways
might play more of a role in one tumor vs. another. To determine if subsets of TCGA
samples might co-express subsets of angiogenic genes, we utilized hierarchical clustering
to cluster 384 genes that were annotated to the angiogenesis Gene Ontology (GO)
category (Figure 2.2A left). Hierarchical clustering is a common form of unsupervised
machine learning, or a type of learning that attempts to cluster input samples into
clusters without any predetermined labeling [92, 93]. Hierarchical clustering has been
widely used on pre-selected gene lists to identify cancer subtypes and associated gene
20
AB
Figure 2.1: Vascularity is heterogeneous among PDAC tumors. (A) Representative exam-
ples of human PDAC (hPDAC) tissue with strong, moderate, and weak CD31 immunoreactivity.
(B) CD31 immunoreactivity is strong in 28% (15/54) of PDAC tissues, moderate in 37% (20/54) of
PDAC tissues, and weak in 35% (19/54) of PDAC tissues.
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signatures [90, 91, 94–98]. From our initial clustering, we observed that there was a
group of 129 genes that was up-regulated in a subset of tumors (Figure 2.2A left). To
focus our analysis on this subset of genes, we extracted those 129 genes and re-clustered
the samples using only this set of genes (Figure 2.2A middle and right). Perou et al.
employed a similar analysis when they extracted an “intrinsic” gene subset from their
original clustering of highly variable genes in breast cancer samples [94] and then used
this “intrinsic” gene set as a starting point in subsequent clustering analyses [95, 98].
While there are other smaller clusters of angiogenic genes not part of the 129 that
are up-regulated in the other pancreatic tumor samples (pointing to other angiogenic
genes and pathways important in those subsets), we decided to focus our analysis on
what could be driving angiogenesis in the subset of tumors that co-express this largest
subset of genes. Overall, the presence of a ‘strong’ pro-angiogenic gene signature
consisting of these 129 genes was found in ∼12% (10/85) of pancreatic tumors.
Because additional samples are being added to TCGA over time with a target goal
of 500 samples, we have re-validated our previously identified pro-angiogenic gene
signature on the updated TCGA sample set of 178 tumors. This updated dataset
consists of 135 PDAC tumors, 14 PDAC tumors with varying subtype designations,
4 colloid (mucinous non-cystic) carcinomas, 1 undifferentiated carcinoma, 8 PNETs,
and 16 of unknown histological type. Patients with PDAC tumors, colloid carcinomas,
or PNETs display varying clinical courses, with PDAC having the worse prognosis
[24, 25]. Because PNETs, in contrast to PDAC tumors, are inherently angiogenic and
densely vascularized, we decided to focus our analysis on the 135 PDAC samples in
combination with the 8 PNET samples [12]. Using our previously determined 129
gene angiogenic signature, hierarchical clustering of RNA-Seq data from these samples
revealed that ∼35% (47/135) of PDAC samples now show a ‘strong’ pro-angiogenic
gene signature while ∼47% (64/135) and ∼18% (24/135) show only a ‘moderate’
or ‘weak’ signature, respectively (Figure 2.2B). Additionally, the PNET and Strong
PDAC groups have a tendency to have higher protein expression of CD31 compared
to the Moderate and Weak PDAC groups, though the differences are not statistically
significant (analysis of variance (ANOVA) P = 0.464) (Figure 2.2C).
2.3 PDACs and PNETs have distinct angiogenesis gene signatures
PDACs and PNETs exhibit an 8% or 53% 5 year survival rate, respectively [24].
Analysis of survival information from TCGA PNET and PDAC groups confirms the
favorable outcome of PNET patients over PDAC patients (Kaplan-Meier log-rank
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Figure 2.2: PDACs have varying degrees of an angiogenic gene signature. (A) Hierarchi-
cal clustering of RNA-Sequencing (RNA-Seq) expression values from 384 genes annotated to the
angiogenesis Gene Ontology (GO) term in 85 pancreatic cancer The Cancer Genome Atlas (TCGA)
samples (left). Extraction (left: white lines, and middle) and re-clustering (right) of a 129 gene
signature up-regulated in a subset of samples (S = strong), whereas some (M = moderate) or few of
these genes (W = weak) are increased in other samples. (B) Hierarchical clustering of RNA-Seq
expression values from 129 angiogenic genes in 8 PNET and 135 PDAC TCGA samples confirms the
presence of PDAC subgroups with Strong, Moderate, and Weak expression of these genes (red =
up-regulated; green = down-regulated). (C) Box plots of TCGA CD31 normalized protein expression
values across the different angiogenic cluster groups. The top, midline, and bottom lines of the
box represent the 25th, 50th, and 75th percentiles, the diamond represents the mean, the whiskers
represent values within 1.5 times the interquartile range, and the dots represent outliers outside that
range.
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test P < 0.01) (Figure 2.3A). There were no observed PNET deaths with a median
follow-up of 1410 days, while the Stage IIB patients in the Strong PDAC and Weak
PDAC groups had a median survival of 592 and 393 days, respectively (Figure 2.3A).
While the difference between the Stage IIB Strong and Weak PDAC groups is not
statistically significant (Kaplan-Meier log-rank test P = 0.17), there was a trend for
the Strong PDAC group to do better (Figure 2.3A). Therefore, this signature is not
prognostic, but it remains to be seen whether the signature could predict response to
anti-angiogenic therapy as no patients received such therapy (Table 2.1).
Table 2.1: Adjuvant drug treatments
Group Drugs
Strong PDAC
Gemcitabine
Gemcitabine + Carboplatin
5-Fluorouracil
5-Fluorouracil + Folinic acid
FOLFOX (Folinic acid + 5-Fluorouracil + Oxaliplatin)
FOLFIRINOX (Folinic acid + 5-Fluorouracil + Irinotecan + Oxaliplatin)
Capecitabine
Cisplatin
Radiation
Weak PDAC
Gemcitabine
Gemcitabine + nab-paclitaxel
Gemcitabine + Capecitabine
5-Fluorouracil
Capecitabine
Radiation
To objectively assess genes up-regulated in the Strong PDAC subgroup and to look
for overlap with those up-regulated in the PNET subgroup, we conducted a differential
expression analysis that compared each of these groups to the Weak PDAC group.
Traditionally, with microarrays, this post-clustering analysis would involve the use
of algorithms like Significance Analysis of Microarrays (SAM) to identify significant
genes within the identified groups [96, 99, 100]. Therefore, we opted to use one of the
many available RNA-Seq based algorithms, DESeq [101], to identify significant genes.
The differential expression analysis revealed that out of the 129 gene signature, 79
are up-regulated between the Strong and Weak PDAC group and 41 are up-regulated
between the PNET and Weak PDAC group (Fold Change (FC) ≥ 1.5, False Discovery
Rate (FDR) < 0.05) (Table 2.2). Overall, 31 genes are commonly up-regulated by
both groups (FC ≥ 1.5, FDR < 0.05) while 48 or 10 genes are uniquely up-regulated
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Figure 2.3: PDACs have varying degrees of an angiogenic gene signature that is distinct
from pancreatic neuroendocrine tumors (PNETs). (A) Kaplan-Meier survival plot of patients
presenting with Stage IIB PDAC and whose tumors express a Strong (n = 34, median: 592 days)
or Weak (n = 15, median: 393 days) angiogenic profile shows no significant difference in overall
survival (OS) (P-value (P) = 0.17) between the two groups, whereas PNET survival is significantly
longer than both PDAC subgroups (P < 0.01). (B) Differential expression analysis of the 129 genes
between the Strong PDAC group vs. the Weak PDAC group and the PNET group vs. Weak PDAC
group reveals that 31 angiogenic genes are common to both tumor types, whereas 48 and 10 are
unique to Strong PDACs or PNETs, respectively (Fold Change (FC) ≥ 1.5, False Discovery Rate
(FDR) < 0.05). (C) Two or three dimensional Principal Component Analysis (PCA) of expression
values from the 129 angiogenic genes in the 8 PNET and 135 PDAC The Cancer Genome Atlas
(TCGA) samples indicates significant variability in the expression of the angiogenic gene signature
among the different groups.
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in the Strong PDAC or PNET groups, respectively (FC ≥ 1.5, FDR < 0.05) (Figure
2.3B, Table 2.2). For example, certain VEGF pathway genes, such as FLT1 (protein:
VEGFR-1), KDR (protein: VEGFR-2), or FLT4 (protein: VEGFR-3), were found
to be commonly up-regulated by both the Strong PDAC and PNET groups while
other genes like ISL1 or SCG2 were uniquely up-regulated in PNETs and ANGPT1,
TEK (protein: TIE2), TIE1, HIF1A, EPAS1 (protein: HIF-2α), TGFBR1, TGFBR2,
and ACVRL1 were uniquely up-regulated by the Strong PDAC group (Table 2.2). To
visualize these results in a different way, the expression values of the 129 genes for all
group samples were subjected to Principal Component Analysis (PCA) in order to
simplify the variability down to either 2 or 3 principal components (PCs) which could
then be visualized on a 2 dimensional or 3 dimensional plane, respectively (Figure
2.3C).
Table 2.2: Expression of 129 angiogenic genes in Strong PDAC and pancreatic neuroendocrine
tumor (PNET) vs. Weak PDAC
Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
90 ACVR1 1.28 0.134419 0.283918 -1.55 0.053462 0.134242
94 ACVRL1 1.76 0.000104 0.000761 1.06 0.697914 0.84304
118 ADD1 1.20 0.276847 0.482664 1.42 0.093408 0.208904
55109 AGGF1 1.25 0.096651 0.220962 1.47 0.089227 0.201602
183 AGT -1.21 0.824471 0.936687 37.33 0.085506 0.195078
284 ANGPT1 3.38 4.31E-08 8.07E-07 1.05 0.742976 0.876605
27329 ANGPTL3 1.15 0.92155 1 17.34 0.006417 0.024057
347 APOD 2.07 0.002255 0.01042 -4.75 0.000466 0.002631
350 APOH 1.57 0.725697 0.874353 42.65 0.018246 0.056763
81575 APOLD1 2.87 2.04E-09 5.67E-08 2.74 2.19E-05 0.000179
358 AQP1 1.34 0.017158 0.055445 -2.24 0.050883 0.129064
83478 ARHGAP24 1.31 0.035347 0.099629 -1.22 0.778738 0.904047
577 BAI3 4.25 0.016713 0.054225 47.69 2.18E-06 2.31E-05
168667 BMPER 4.36 0.001766 0.00849 12.06 6.04E-05 0.000439
718 C3 2.10 1.30E-05 0.000124 -9.90 5.24E-12 1.98E-10
719 C3AR1 3.23 2.08E-11 1.04E-09 -1.62 0.032684 0.091125
729 C6 2.32 0.005793 0.022837 -1.03 0.789036 0.911819
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 31 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
79 differentially expressed genes in Strong PDAC vs. Weak PDAC (79 up-regulated, 0
down-regulated); 50 differentially expressed genes in PNET vs. Weak PDAC (41 up-regulated, 9
down-regulated); Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
10203 CALCRL 4.15 3.29E-19 1.72E-16 1.91 0.001772 0.008227
729230 CCR2 5.70 3.24E-13 2.90E-11 -1.83 0.100532 0.220636
947 CD34 2.31 4.65E-09 1.15E-07 1.89 0.001753 0.008154
25932 CLIC4 2.75 5.92E-12 3.47E-10 -1.48 0.066506 0.159899
1215 CMA1 11.66 0.001092 0.005646 1.38 0.379612 0.586507
1306 COL15A1 3.20 2.23E-15 4.01E-13 -1.94 0.006385 0.023948
1285 COL4A3 3.72 0.001814 0.008666 1.11 0.824543 0.939269
1464 CSPG4 1.02 0.75723 0.893452 -1.31 0.447436 0.653026
1524 CX3CR1 2.85 6.95E-06 7.15E-05 2.29 0.014731 0.047777
6387 CXCL12 3.48 2.35E-11 1.16E-09 -1.29 0.983107 1
1545 CYP1B1 7.40 1.51E-29 1.50E-25 -1.37 0.095421 0.211965
57105 CYSLTR2 4.06 0.000438 0.002612 7.66 0.000206 0.001284
23405 DICER1 1.49 0.004659 0.019015 1.66 0.019014 0.058703
641700 ECSCR 1.69 0.004009 0.01686 1.42 0.179689 0.343343
54583 EGLN1 1.00 0.882916 0.976375 -1.16 0.580403 0.749433
2004 ELK3 2.62 1.16E-08 2.57E-07 -1.24 0.340933 0.54456
2028 ENPEP 2.73 2.38E-08 4.86E-07 1.66 0.04932 0.126023
2034 EPAS1 1.65 0.000206 0.001367 1.53 0.028162 0.080727
2047 EPHB1 3.18 0.043333 0.117391 2.63 0.231459 0.412084
51752 ERAP1 1.28 0.068527 0.16901 -1.11 0.624052 0.784646
356 FASLG 2.80 0.051675 0.135245 -1.52 0.642535 0.798728
2254 FGF9 1.94 0.06792 0.167857 3.84 0.006958 0.025646
2260 FGFR1 1.87 1.11E-06 1.43E-05 3.24 3.92E-10 1.02E-08
2263 FGFR2 -1.16 0.420471 0.640822 -17.60 3.68E-16 3.17E-14
2277 FIGF 3.59 0.018226 0.058344 3.28 0.06252 0.15215
2321 FLT1 2.11 1.30E-08 2.83E-07 3.36 1.04E-09 2.43E-08
2324 FLT4 2.46 1.25E-07 2.07E-06 3.77 2.77E-08 4.76E-07
51738 GHRL 1.41 0.288334 0.496086 -6.85 0.052634 0.132638
2702 GJA5 1.87 0.000107 0.000777 -1.03 0.829247 0.943158
10672 GNA13 1.73 0.000231 0.001498 -1.25 0.254681 0.441674
2822 GPLD1 3.50 0.006407 0.024772 21.29 1.37E-06 1.53E-05
25960 GPR124 2.89 1.72E-12 1.21E-10 1.69 0.01807 0.056321
26585 GREM1 3.82 0.00029 0.001829 -3.27 0.016599 0.05258
2969 GTF2I 1.37 0.039113 0.108126 2.22 9.34E-05 0.000647
9421 HAND1 42.99 0.256031 0.456074 26.50 0.196605 0.366146
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 31 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
79 differentially expressed genes in Strong PDAC vs. Weak PDAC (79 up-regulated, 0
down-regulated); 50 differentially expressed genes in PNET vs. Weak PDAC (41 up-regulated, 9
down-regulated); Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
9464 HAND2 2.28 0.000147 0.001022 1.43 0.330874 0.533066
9734 HDAC9 1.82 0.009783 0.034952 1.22 0.512487 0.707316
3087 HHEX -1.02 0.837256 0.946165 -1.56 0.184215 0.349603
3091 HIF1A 2.01 2.14E-06 2.54E-05 -1.24 0.259919 0.447496
204851 HIPK1 1.63 0.000516 0.003004 1.19 0.388465 0.594742
28996 HIPK2 1.35 0.02309 0.070767 2.66 1.52E-06 1.67E-05
9394 HS6ST1 1.30 0.064347 0.160585 1.12 0.508225 0.705822
3553 IL1B 1.82 0.037926 0.105491 -1.44 0.366107 0.571362
3670 ISL1 1.69 0.178856 0.350616 19.37 1.82E-06 1.97E-05
3685 ITGAV 2.20 1.10E-07 1.86E-06 -2.45 4.19E-05 0.000321
3688 ITGB1 1.68 0.000343 0.002112 -1.41 0.101044 0.22149
83700 JAM3 1.75 0.000241 0.001559 1.61 0.02388 0.070574
3791 KDR 3.04 4.57E-14 5.61E-12 4.37 2.56E-13 1.29E-11
11061 LECT1 1.38 0.560306 0.772961 1.65 0.554378 0.730645
6885 MAP3K7 1.57 0.004483 0.018433 1.10 0.663338 0.814751
4162 MCAM 1.96 2.13E-06 2.54E-05 1.74 0.011287 0.038288
5469 MED1 1.33 0.073878 0.178863 1.19 0.558488 0.733027
4223 MEOX2 3.63 2.35E-08 4.81E-07 -1.08 0.861664 0.966734
79812 MMRN2 2.25 2.82E-08 5.62E-07 1.79 0.003774 0.015521
92140 MTDH 1.34 0.036302 0.101787 -1.21 0.358553 0.563493
80155 NAA15 1.18 0.212152 0.398612 -1.16 0.530401 0.713916
4763 NF1 1.39 0.022444 0.069223 1.47 0.103588 0.225862
4775 NFATC3 1.22 0.140951 0.2946 -1.64 0.064087 0.155272
4881 NPR1 2.48 2.86E-08 5.69E-07 2.63 2.71E-05 0.000217
4897 NRCAM 2.39 1.15E-05 0.000112 13.16 2.44E-15 1.74E-13
8829 NRP1 2.38 8.17E-10 2.59E-08 1.32 0.111065 0.238476
9378 NRXN1 4.30 5.12E-06 5.47E-05 20.78 3.32E-12 1.31E-10
9369 NRXN3 3.83 0.000877 0.004694 12.05 7.04E-06 6.57E-05
116150 NUS1 1.29 0.043239 0.117168 1.03 0.757191 0.887489
55742 PARVA 1.36 0.025279 0.076065 -2.06 0.004041 0.016436
5140 PDE3B 2.34 0.004105 0.017186 5.72 2.92E-05 0.000232
5290 PIK3CA 2.24 1.89E-06 2.27E-05 -1.28 0.31137 0.510688
5294 PIK3CG 5.16 1.46E-12 1.06E-10 -2.09 0.010269 0.035493
5316 PKNOX1 1.13 0.400487 0.619976 1.14 0.441351 0.647094
57125 PLXDC1 1.95 3.71E-05 0.000311 1.53 0.138244 0.281608
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 31 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
79 differentially expressed genes in Strong PDAC vs. Weak PDAC (79 up-regulated, 0
down-regulated); 50 differentially expressed genes in PNET vs. Weak PDAC (41 up-regulated, 9
down-regulated); Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
23129 PLXND1 1.63 0.001399 0.006985 1.27 0.36716 0.572789
23509 POFUT1 1.24 0.100837 0.228037 1.53 0.041843 0.111043
5578 PRKCA 1.03 1 1 -1.81 0.004233 0.017093
5613 PRKX 1.35 0.076365 0.183542 -3.49 1.54E-05 0.000132
84432 PROK1 4.43 0.110425 0.244269 -1.46 1 1
60675 PROK2 2.95 0.433556 0.654636 -1.97 0.831581 0.94463
5728 PTEN 1.57 0.000789 0.004287 -1.04 0.943968 1
5787 PTPRB 2.19 1.37E-07 2.22E-06 2.66 1.21E-05 0.000106
5797 PTPRM 1.76 8.35E-05 0.00063 2.64 8.02E-07 9.52E-06
10266 RAMP2 1.50 0.003989 0.016798 1.83 0.004153 0.016826
6091 ROBO1 3.82 1.68E-16 4.23E-14 -1.17 0.463909 0.668963
54538 ROBO4 1.97 6.59E-06 6.84E-05 2.79 2.22E-06 2.35E-05
6093 ROCK1 1.67 0.001488 0.007347 -1.09 0.542624 0.722145
9475 ROCK2 1.74 0.000324 0.002018 -1.49 0.081406 0.187464
6095 RORA 2.53 4.57E-09 1.13E-07 1.88 0.004834 0.019105
1901 S1PR1 3.52 2.73E-16 6.45E-14 1.65 0.013022 0.043103
23328 SASH1 2.69 1.71E-10 6.53E-09 2.27 1.61E-05 0.000137
7857 SCG2 3.51 0.057532 0.147316 65.37 7.42E-06 6.87E-05
9723 SEMA3E 3.64 0.000257 0.001651 4.75 0.001244 0.006095
29072 SETD2 1.32 0.051775 0.135422 1.22 0.301772 0.499009
6422 SFRP1 9.57 4.36E-07 6.22E-06 29.50 1.53E-09 3.46E-08
23411 SIRT1 1.67 0.001562 0.00765 1.24 0.358061 0.562989
9990 SLC12A6 1.42 0.038293 0.10623 -1.08 0.662316 0.81414
9353 SLIT2 8.61 1.44E-22 1.90E-19 2.52 0.002719 0.011783
6722 SRF 1.15 0.357784 0.575258 -1.12 0.67388 0.823416
6733 SRPK2 1.49 0.006965 0.026514 2.14 0.00067 0.00359
23166 STAB1 2.29 2.32E-08 4.76E-07 1.19 0.527104 0.712285
6886 TAL1 2.52 0.000161 0.001104 2.60 0.004552 0.018169
7010 TEK 3.74 1.13E-14 1.57E-12 1.65 0.026744 0.077372
7046 TGFBR1 1.53 0.00904 0.032787 -1.02 0.751031 0.883048
7048 TGFBR2 1.86 4.36E-05 0.000356 -1.56 0.018017 0.056204
7060 THBS4 5.55 7.95E-11 3.27E-09 1.98 0.068252 0.163316
221981 THSD7A 4.72 7.58E-11 3.14E-09 -1.08 0.708204 0.850732
7075 TIE1 2.21 1.46E-07 2.35E-06 1.58 0.026074 0.075776
55273 TMEM100 3.80 4.42E-05 0.00036 5.52 0.000318 0.001886
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 31 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
79 differentially expressed genes in Strong PDAC vs. Weak PDAC (79 up-regulated, 0
down-regulated); 50 differentially expressed genes in PNET vs. Weak PDAC (41 up-regulated, 9
down-regulated); Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
164656 TMPRSS6 -1.49 0.641486 0.833109 23.17 0.02359 0.069884
23554 TSPAN12 1.00 0.885861 0.978542 3.37 0.000204 0.001275
7342 UBP1 1.19 0.231426 0.42474 -1.16 0.564326 0.736234
22846 VASH1 2.06 1.72E-06 2.10E-05 3.61 2.33E-09 5.06E-08
10451 VAV3 1.56 0.068866 0.169688 2.21 0.035368 0.09703
7716 VEZF1 1.33 0.033594 0.095708 1.73 0.007181 0.026347
10163 WASF2 1.58 0.001278 0.006463 -1.17 0.490966 0.692833
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 31 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
79 differentially expressed genes in Strong PDAC vs. Weak PDAC (79 up-regulated, 0
down-regulated); 50 differentially expressed genes in PNET vs. Weak PDAC (41 up-regulated, 9
down-regulated); Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
To further delineate the differences between these two groups, the 10 unique PNET
genes, 48 unique Strong PDAC genes, and the 31 common genes were analyzed using
GeneMANIA to identify which of these gene products participate in the same pathway
(Figure 2.4, black: common genes, pink: unique to Strong PDAC, mustard: unique
to PNET) [102]. After removal of any unconnected genes from the network, it was
found that in addition to up-regulation of VEGF pathway genes, PDACs and PNETs
also commonly up-regulate FGFR1, S1PR1, and PTPRB (Figure 2.4). S1P is a
pro-angiogenic sphinogolipid that is known to act through S1PR1 [103] while PTPRB
has been shown to regulate the spreading and migration of ECs during angiogenesis
[104].
However, these commonly up-regulated gene products are only highly connected
to one another via angiogenic molecules that are uniquely up-regulated in PDAC
(Figure 2.4). Very few connections are found between the gene products that are
uniquely up-regulated in PNETs, suggesting that such connections are still unknown.
PDACs also up-regulate many other highly connected pro-angiogenic genes, including
TGFBR1, TGFBR2, HIF1A, ANGPT1, and several integrins/collagens (ITGAV,
ITGB1, COL4A3, COL15A1).
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Figure 2.4: Interconnectivity of angiogenesis genes unique to the Strong PDAC group,
unique to PNETs, or common to both. After GeneMANIA pathway analysis of 48, 10, and
31 genes uniquely up-regulated in the Strong PDAC group, the PNET group, or common between
them, respectively, 22, 2, and 6 interconnected angiogenesis related genes remain. Common genes
(black) are dominated by vascular endothelial growth factor (VEGF) pathway members, while genes
unique to the Strong PDAC group (pink) also involve integrins, collagens, HIF1A, and TGF-β related
pathway members. Genes unique to PNET (mustard) do not have known pathway connections except
for ANGPTL3 and FGF9.
2.4 Isolated PDAC mutations do not explain the presence of an angio-
genic gene signature
To determine if the different angiogenic groups are associated with a specific
mutational burden, we gleaned curated mutation data from TCGA dataset which
includes information on 98 PDAC and 3 PNET cases. Overall, PDACs exhibit more
non-silently mutated genes (median = 47) than PNETs (median = 19) (P = 0.0232,
Wilcoxon rank sum test) (Figure 2.5A). Additionally, the PNET (median = 19), Strong
PDAC (median = 40), Moderate PDAC (median = 48), and Weak PDAC (median
= 64) groups differ significantly (P = 0.0003, Kruskal-Wallis rank sum test) (Figure
2.5A). Specifically, the Strong and Weak PDAC group are significantly different (P =
31
0.0038, post-hoc Wilcoxon rank sum test with Bonferroni correction) as well as the
PNET and Moderate PDAC group (P = 0.0442, post-hoc Wilcoxon rank sum test
with Bonferroni correction).
KRAS (86%, 84/98), TP53 (55%, 54/98), SMAD4 (19%, 19/98), and CDKN2A
(19%, 19/98) were four of the five most frequently mutated genes across the PDAC
samples (Figure 2.5A, Table 2.3), and except for KRAS, their mutation frequencies
are consistent with recent PDAC genome sequencing studies (KRAS 92-100%, TP53
33-84%, SMAD4 16-33%, CDKN2A 2-24%) [27, 28, 105, 106]. Because SMAD4
[107–109] and CDKN2A [110] are often altered via deletion in addition to mutation,
analysis of TCGA copy number data indicated that SMAD4 and CDKN2A are also
deleted in 14% (19/134) and 26% (35/134) of PDAC samples, respectively (Figure
2.5B). TTN, which codes for a giant muscle protein consisting of ∼27,000 to ∼33,000
amino acids depending on the isoform, was also found to be one of the top five most
frequently mutated genes (20.4%, 20/98) in PDAC (Figure 2.5A, Table 2.3). However,
due to its massive size, lack of potential cancer causing role, and frequent mutation in
other cancer genome studies, it is often considered to be a false positive [111, 112].
To determine if a mutation in any single gene could explain the expression of the
angiogenic gene signature, the mutation frequencies of all genes were compared between
the Strong and Weak PDAC groups. This showed that only one gene, KBTBD6,
differed significantly between the two groups, with 0/41 mutations in the Strong PDAC
group and 5/19 (26%) mutations in the Weak PDAC group (P < 0.05) (Table 2.3).
KBTBD6 is a substrate adaptor in an E3 CUL3 RING ubiquitin ligase complex that
so far has only been shown to mediate ubiquitination and proteasomal degradation of
TIAM1, a RAC1 specific guanine exchange factor (GEF) [113]. KBTBD6 currently has
no known angiogenic role, but it is likely to be involved in the proteasomal degradation
of other proteins which theoretically could have such a role.
2.5 TGF-β is an upstream regulator of genes from the angiogenic gene
signature
To determine other potential drivers of the angiogenic gene signature, we subjected
the 79 differentially expressed angiogenesis genes from the signature to Ingenuity
Pathway Upstream Regulator Analysis and identified TGF-β as a major upstream
regulator of 17 of the 79 genes (P = 1.17E-11) (Table 2.4). Because this suggests that
the Strong PDAC group might exhibit a TGF-β signaling signature, we identified
a set of 188 TGF-β responsive genes from the TGFB UP.V1 UP gene set from the
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Figure 2.5: Median mutation counts and frequently mutated or deleted genes in PDAC.
(A) The top 34 non-silently mutated genes that appear with a frequency of 6% or more in the 3
PNET + 98 PDAC cases combined are listed on the left while their mutation frequencies in PDAC
alone are graphed to the right. Samples (left) appear in the same order as the angiogenic cluster
analysis with (top) blue indicating a non-silently mutated gene, white a silently mutated or wild type
(WT) gene, and gray a sample lacking mutation data. Total counts (below) of non-silently mutated
genes in 3 PNET and 98 PDAC samples were graphed with median counts as follows: PNET: 19,
PDAC: 47, Strong PDAC: 40, Moderate PDAC: 48, Weak PDAC: 64. (B) (Left) Distribution of
the top 7 PDAC deep deletions across the different PNET and PDAC angiogenic groups (8 PNET
and 134 of 135 PDAC samples had copy number data. The missing PDAC sample is shown in gray).
Several samples show deletion of many of these genes due to the top 6 genes appearing within the
same cytoband. (Right) Frequency of the top 7 PDAC genes with deep deletions. Frequency is shown
as overall percent of deletion in the 134 samples with copy number data.
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Gene Set Enrichment Analysis (GSEA) Molecular Signatures Database (MSigDB)
in order to query their expression values across the different PDAC samples. This
gene set represents genes up-regulated in a panel of epithelial cell lines by TGF-β.
From this gene set, two genes, FLT4 and ELK3, were already a part of the angiogenic
gene signature, and were thus removed from the gene set to avoid any overlap with
the existing angiogenesis analysis. To visualize the expression of the remaining 186
TGF-β responsive genes across the different PDAC samples, we performed hierarchical
clustering of the genes while preserving the order of the patient samples according to
how they clustered in the angiogenesis analysis (Figure 2.6A).
Table 2.4: Angiogenic TGF-β responsive genes
Gene Symbol Gene Name
TGFBR2 transforming growth factor beta receptor II
TGFBR1 transforming growth factor beta receptor I
RORA RAR related orphan receptor A
RAMP2 receptor (G protein-coupled) activity modifying protein 2
NRP1 neuropilin 1
ITGB1 integrin subunit beta 1
ITGAV integrin subunit alpha V
HIF1A hypoxia inducible factor 1 alpha subunit
GREM1 gremlin 1, DAN family BMP antagonist
GNA13 guanine nucleotide binding protein (G protein), alpha 13
FLT1 fms related tyrosine kinase 1 (protein: VEGFR-1)
FGFR1 fibroblast growth factor receptor 1
ELK3 ELK3, ETS transcription factor
CLIC4 chloride intracellular channel 4
CCR2 chemokine (C-C motif) receptor 2
C3AR1 complement component 3a receptor 1
ACVRL1 activin A receptor type IL
From this analysis, it is clear that the Strong PDAC group up-regulates a subset
of TGF-β target genes compared to the Moderate or Weak PDAC groups (Figure
2.6A). To determine which of these genes meets statistical significance, differential
expression analysis between the Strong and Weak PDAC groups confirms that 50
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Figure 2.6: Angiogenic gene signature correlates with increased expression of TGF-β
target genes and wild type (WT) SMAD4. (A) While preserving the order of the 8 PNET and
135 PDAC The Cancer Genome Atlas (TCGA) patient samples according to the angiogenesis cluster
analysis, hierarchical clustering of TCGA RNA-Sequencing (RNA-Seq) expression values from 186
TGF-β responsive genes indicates that a subset of TGF-β target genes (white box) is up-regulated in
the Strong PDAC group (red = up-regulated; green = down-regulated). (B) (Top) Distribution of
SMAD4 mutations or deletions across the clustered TCGA samples. (Bottom) Overall SMAD4 loss
by mutation or deletion was significantly higher in the Moderate (M) (37%) and Weak (W) (42%)
PDAC subgroups compared with the Strong (S) (13%) PDAC subgroup. Stacked bars show the total
percent of patients in each subgroup with SMAD4 mutations (solid bars) or deletions (hatched bars)
(*P-value (P) < 0.05).
TGF-β target genes are up-regulated, including pro-angiogenic CTGF (FC 3.33, FDR
1.86E-06) and ITGA5 (FC 1.88, FDR 0.007113) (Table S1). Additionally, TGFB3,
but not TGFB1 or TGFB2, is up-regulated in the Strong PDAC group (FC 3.40, FDR
1.31E-10). Analysis of PDAC tissues has also shown that there is an abundance of
phosphorylated SMAD2 (p-SMAD2) in pancreatic cancer cell (PCC) and stromal cell
nuclei [114].
Since SMAD4 is a critical mediator of TGF-β signaling that is often inactivated
by mutation or deletion in PDAC, we investigated its mutation or copy number status
across the different PDAC groups and found that it was only altered in 13% of cases
in the Strong PDAC group, but in 37% and 42% of cases in the Moderate and Weak
PDAC groups, respectively (Figure 2.6B). This inactivation rate in the Strong PDAC
group is significantly different from the rate in the Moderate (P = 0.017261) and Weak
(P = 0.017587) PDAC groups and supports the finding of active TGF-β signaling in
the Strong PDAC group.
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Because immunohistochemical staining or immunoblotting of SMAD4 protein has
been shown to correlate with its wild type (WT) status [109] and TCGA has protein
array information on SMAD4 and CD31, we did a correlation analysis between SMAD4
and CD31 protein expression in TCGA samples (Figure 2.7A). We found that SMAD4
and CD31 protein expression is significantly correlated with a correlation coefficient
of +0.70 (P = 2.60e-14) for all samples, and a correlation coefficient of +0.72 (P =
1.20e-14) for just the PDAC samples.
To confirm these findings, we assessed SMAD4 and CD31 protein expression in a
tissue microarray (TMA) of 54 hPDAC tissues using CD31 and WT SMAD4 detecting
antibodies (Figure 2.7B) [109]. Nuclear SMAD4 was present in the cancer cell nuclei
of 23 PDACs in which CD31-positive ECs and vessels were abundant (Figure 2.7B).
By contrast, wild-type SMAD4 immunoreactivity was not detectable in the cancer
cells in 31 PDACs, and in these tissues CD31 immunoreactivity was sparse (Figure
2.7B). These data therefore suggest that the presence of wild-type SMAD4 in PCCs
correlates with EC abundance.
2.6 PDACs with an angiogenesis gene signature are enriched in inflam-
mation related genes
To identify additional pathways active in the Strong PDAC group vs. the Weak
PDAC group, we subjected a ranked list of genes sorted by their FC differences between
the two groups to GSEA. GSEA indicated that the Strong PDAC group is dominated
by expression of inflammatory genes as evidenced by major overlap with hallmark
genes involved in transplant rejection (Figure 2.8A) or the inflammatory response
(Figure 2.8B). Moreover, leading edge analysis of these GSEAs indicated that genes
up-regulated in the Strong PDAC group include both pro-inflammatory members,
such as CD28, IL6, JAK2, CCR7, LTA, OSMR, and TLR2, and anti-inflammatory
members, such as SOCS3, IL2RA, and MEFV.
To further explore this balance between pro- and anti-inflammatory molecules,
gene expression values for 85 positive regulators and 81 negative regulators of the
inflammatory response were visualized using hierarchical clustering of the genes while
preserving the order of the patient samples according to how they clustered in the
angiogenesis analysis (Figure 2.9A). This analysis indicates that many more positive
regulators are up-regulated than negative regulators in the Strong PDAC group (Figure
2.9A). Differential expression analysis confirms that 28 positive regulators are up-
regulated compared to only 16 negative regulators in the Strong PDAC group vs. the
37
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Figure 2.7: Correlation of CD31 and SMAD4 protein expression. (A) Analysis of protein
expression data from The Cancer Genome Atlas (TCGA) shows that SMAD4 and CD31 levels
correlate in pancreatic cancer (PNET+PDAC: r = +0.70, PDAC: r = +0.72, P-value (P) < 0.01).
(B) (Top) Representative images of the SMAD4 and CD31 immunostaining on the tissue microarray
(TMA) shows that CD31 positive endothelial cells (ECs) and vessels (arrowhead) are present in
PDACs with SMAD4 immunoreactivity in the pancreatic cancer cells (PCCs) (left panels), whereas
in SMAD4 negative tumors, CD31 immunoreactivity is rarely present (right panels). Insets show
magnified images of boxed areas. Scale bars 50 µm. (Bottom) Quantification of CD31 and SMAD4
immunostaining of a human PDAC (hPDAC) TMA shows that in SMAD4 positive tumors (open
bar), CD31 immunoreactivity is significantly higher than in SMAD4 negative tumors (closed bar)
(**P < 0.01).
Weak PDAC group (FC >= 1.5, FDR < 0.05) (Table S2 and S3). Additionally, only 7
positive regulators are down-regulated while 17 negative regulators are down-regulated
(FC <= −1.5, FDR < 0.05) (Table S2 and S3).
Additional investigation of these inflammatory gene lists revealed up-regulation
of several genes related to the IL6–JAK–STAT3 signaling pathway, including IL6,
both components of the IL6 signaling complex, IL6R and IL6ST, as well as JAK2
and another IL6 family member, OSMR, that can transduce signals through STAT3.
Moreover, analysis of additional known JAK–STAT pathway genes revealed that 40
additional genes in this pathway are up-regulated including JAK1, JAK3, STAT1,
STAT4, PIAS2, and 4 different SOCS genes (Figure 2.9B, Table S4).
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Figure 2.8: Angiogenic PDACs also demonstrate an inflammatory profile. (A) Gene Set
Enrichment Analysis (GSEA) indicates that genes up-regulated during transplant rejection correlate
with genes up-regulated in the Strong PDAC subgroup when compared to the Weak PDAC subgroup
(family-wise error rate (FWER) < 0.001). (B) GSEA indicates that genes up-regulated during
the inflammatory response correlate with genes up-regulated in the Strong PDAC subgroup when
compared to the Weak PDAC subgroup (FWER < 0.001).
2.7 TGF-β receptor type-1 and JAK inhibition blocks angiocrine effects
Our findings indicate that PDACs in the Strong PDAC subgroup are associated
with increased expression of TGF-β target genes and an inflammation signature in
which several pro-inflammatory genes, including JAK1 and JAK2 were increased.
Moreover, the Strong PDAC group expresses wild-type SMAD4 protein that correlates
with CD31 levels. Therefore, we next sought to determine whether inhibition of
the TGF-β receptor type-1 (gene: TGFBR1) and/or JAK signaling pathways can
block angiogenic effects. We used the well-known PANC-1 human PCCs, as well as
our recently established IUSCC-PC1 cell line in 3-dimensional (3D) co-cultures with
non-immortalized human vascular endothelial cells (HUVECs). Both PANC-1 cells
and IUSCC-PC1 cells harbor mutated KRAS (KRASG12D/+) and express wild-type
SMAD4 as determined by DNA sequencing. Importantly, establishing new PCCs
diminishes the potential for additional mutations and clonal selections that may arise
from serial in vivo and in vitro passaging. Thus, IUSCC-PC1 cells were used to
confirm findings with PANC-1 cells which were established in 1975 [115].
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Figure 2.9: Angiogenic PDACs exhibit up-regulation of both pro-inflammatory and
anti-inflammatory molecules and are enriched in JAK/STAT signaling genes. (A) While
preserving the order of the 8 PNET and 135 PDAC The Cancer Genome Atlas (TCGA) patient
samples according to the angiogenesis cluster analysis, hierarchical clustering of RNA-Sequencing
(RNA-Seq) expression values from 85 positive (top) or 81 negative (bottom) regulators of inflammation
indicates that the Strong PDAC subgroup up-regulates subsets (white boxes) of both positive and
negative regulators of inflammation (red = up-regulated; green = down-regulated). Differential
expression analysis reveals up-regulation of 28 positive and 16 negative regulators of inflammation
and down-regulation of 7 positive and 17 negative regulators of inflammation, suggesting a tipping
of the scale to a pro-inflammatory environment (|Fold Change (FC)| >= 1.5, False Discovery Rate
(FDR) < 0.05). (B) Compared with the Weak PDAC group, 40 or 8 JAK/STAT signaling pathway
genes are up-regulated in the Strong or Moderate PDAC groups, respectively (FC >= 1.5, FDR <
0.05) (red = up-regulated; green = down-regulated; gray = not differentially expressed).
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To monitor changes in the growth for each cell type in the co-culture studies,
PCCs and HUVECs were labeled with green and red fluorescence, respectively. By
comparison to 3D cultures in which PCCs and HUVECs were cultured separately
(Figure 2.10A (DMSO rows, PCC and EC columns) and 2.10B), IUSCC-PC1 and
PANC-1 cell proliferation was significantly enhanced by co-culture with HUVECs
(Figure 2.10A (DMSO rows, merged column) and 2.10B). Moreover, HUVEC pro-
liferation was enhanced in co-cultures with either PCC line (Figure 2.10A (DMSO
rows, merged column) and 2.10B). These mitogenic effects were completely blocked by
the combination of the JAK1/JAK2 inhibitor, ruxolitinib [100 nM], and the TGF-β
receptor type-1 inhibitor, SB505124 [2 µM] (Figure 2.10A (DMSO vs. SB+Rux rows,
merged column) and 2.10B), but not by either inhibitor alone [100 nM ruxolitinib or
2 µM SB505124] (Figure 2.10B). These results therefore suggest that human PCCs
exert growth-promoting angiogenic effects on ECs, that ECs exert mitogenic effects
on PCCs, and that these events are suppressible by combinatorial targeting of JAK
and TGF-β signaling pathways.
2.8 SB505124+Ruxolitinib block pancreatic cancer cell (PCC) mediated
activation of JAK1 in endothelial cells (ECs)
Because ruxolitinib selectively targets JAK1 and JAK2 [116], we next assessed
whether one or both of these kinases are involved in the mitogenic crosstalk between
human PCCs and HUVECs. Phosphorylated JAK1 (p-JAK1) was only detectable in
co-cultures of PCCs and HUVECs, and its levels were suppressed by the combination
of SB505124 and ruxolitinib (Figure 2.11A). By contrast, JAK2 phosphorylation was
not affected by co-culture, or by SB505124 and ruxolitinib (Figure 2.11A). Moreover,
this combination failed to induce cleaved PARP (gene: PARP1) in PCCs or HUVECs,
or in co-cultures of these cells (Figure 2.11A). To determine whether increased p-JAK1
occurred in HUVECs, PCCs or both cell types, we added conditioned media (CM)
from IUSCC-PC1 or PANC-1 cells to HUVECs, and, conversely, CM from HUVECs
to PCCs. CM from the PCCs markedly enhanced p-JAK1 levels and induced SMAD
phosphorylation in HUVECs (Figure 2.11B). By contrast, CM from HUVECs failed
to induce JAK1 phosphorylation in the PCCs, but stimulated SMAD phosphorylation
(Figure 2.11C). Thus, JAK1 activation is EC specific whereas canonical TGF-β
signaling pathways are activated in both cell types.
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Figure 2.10: TGF-β receptor type-1 and JAK1/JAK2 inhibition suppress human pan-
creatic cancer cell (PCC) and endothelial cell (EC) growth. (A) 3-dimensional (3D) co-
cultures of IUSCC-PC1 or PANC-1 human pancreatic cancer cells (PCCs) (green) and human
endothelial cells (ECs) (human vascular endothelial cells (HUVECs), red) shows that compared with
vehicle (DMSO [0.05%]), ruxolitinib [100 nM] together with SB505124 [2 µM] suppress PCC and
EC growth. Shown are representative brightfield and fluorescent images from three independent
experiments. Scale bars, 200 µm. (B) Fluorescence intensity quantification shows that compared
with 3D cultures in which IUSCC-PC1 or PANC-1 PCCs and HUVECs are cultured independently
(closed bars), culturing ECs and PCCs together in 3D (open bars) significantly enhances PCC and
EC growth, which is completely blocked when ruxolitinib and SB505124 are combined, but not by
either inhibitor alone. Data are mean ± standard error of the mean (SEM) from three independent
experiments. *P-value (P) < 0.05, and **P < 0.01.
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Figure 2.11: SB505124+Ruxolitinib block PCC mediated activation of JAK1 in ECs.
(A) Immunoblots with 3-dimensional (3D) culture lysates from IUSCC-PC1 or PANC-1 human
pancreatic cancer cells (PCCs) with or without human vascular endothelial cells (HUVECs) (endothe-
lial cells (ECs)) show that endothelial (CD31) and epithelial (CK19 (gene: KRT19)) markers are
present in PCC:EC co-cultures, in which phosphorylated JAK1 (p-JAK1) but not phosphorylated
JAK2 (p-JAK2) levels are markedly increased. SB505124 [2 µM] together with ruxolitinib [100 nM]
suppresses p-JAK1, but does not induce PARP (gene: PARP1) cleavage. By contrast, gemcitabine
(Gem, [10 µM]) enhances cleaved PARP levels in co-cultured cells. (bottom) Quantification confirms
that SB505124 and ruxolitinib (open bars) significantly decreases p-JAK1 levels in co-cultured cells.
(B-C) Immunoblots with EC (B) or PCC (C) lysates show that conditioned media (CM) from PCCs
increases p-JAK1 and phosphorylated SMAD (p-SMAD) levels in ECs (B, top), whereas CM from
ECs increases p-SMAD levels in PCCs (C, top). Quantification confirms that PCC CM (B, bottom,
open bars) significantly increases p-JAK1 and p-SMAD in ECs, and that EC CM (C, bottom, open
bars) significantly increases p-SMAD in PCCs. ERK2 in A, B, and C confirms equivalent lane
loading. Data in A, B, and C are presented as mean ± standard error of the mean (SEM) from three
independent experiments. *P-value (P) < 0.05, #P < 0.01.
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To assess the role of JAK1 in EC growth, and in mediating angiocrine effects on
PCCs we used small hairpin RNAs (shRNAs) to suppress JAK1 expression in HUVECs.
Both shRNAs markedly attenuated JAK1 expression levels in HUVECs (Figure 2.12A),
and suppressed their proliferation (Figure 2.12B) and ability to stimulate PCC growth
(Figure 2.12C). Therefore, endothelial JAK1 is required for the angiocrine effects of
ECs on PCCs.
The JAK1/JAK2 inhibitor, ruxolitinib [100 nM], and the TGF-β receptor type-1
inhibitor, SB505124 [2 µM], have no effect on IUSCC-PC1 proliferation in single cell
type 3D cultures (Figure 2.13). Therefore, we did not deem it necessary to perform
additional single culture experiments assessing proliferation with the inhibitors. In-
stead, we focused on what happens in the co-culture setting due to our findings from
the mechanistic studies. We know that JAK1 is not phosphorylated in single 3D cul-
tures of IUSCC-PCC1, PANC-1, or HUVECs with or without SB505124+Ruxolitinib
treatment (Figure 2.11A), and that there is a lack of p-SMAD2/3 when HUVECs are
cultured alone (Figure 2.11B, no CM timepoint). CM from each cell type placed on
the other cell type also leads to an increase in p-SMAD2/3 beyond what is observed
in single culture for both cell types (Figure 2.11B-C). Increases in p-JAK1 only occur
when the two cell types are co-cultured (Figure 2.11A), and CM experiments indicate
that this phosphorylation is exclusive to the ECs (Figure 2.11B). Treatment of the
co-cultures with SB505124+Ruxolitinib leads to a decrease in this p-JAK1 (Figure
2.11A). While knocking down JAK1 in ECs does lead to a decrease in their prolifera-
tion alone (Figure 2.12B), it also suppresses PCC growth in co-culture experiments
(Figure 2.12C), suggesting the importance of this EC pathway in stimulating the PCC
growth (Figure 2.12C).
2.9 KRC mice exhibit abundant tumor angiogenesis
KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) mice, which express oncogenic Kras in
the pancreas, but lack Rb1 function, exhibit rapid pancreatic intraepithelial neoplasia
(PanIN) formation and progression to murine PDAC (mPDAC) with a median survival
of 10 weeks [117]. While RB1 mutations are rare (0-1%) in hPDAC [27–29, 105, 106],
loss of RB1 function is common [91, 106, 114]. KRC mPDACs express high levels of
pro-angiogenic cytokines [117], and so we sought to determine whether KRC mPDACs
exhibit angiogenesis. CD31 (gene: Pecam1) immunoreactivity in KRC mPDAC was
present in sinusoidal-like blood vessels within the collagen-rich stroma adjacent to
CK19 (gene: Krt19) positive cancer cells (Figure 2.14A), and in relatively larger
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Figure 2.12: JAK1 is required for EC growth and angiocrine effects on PCCs. (A-B)
Two different JAK1 targeting shRNAs decrease JAK1 expression in human vascular endothelial cells
(HUVECs) (A), and significantly decrease HUVEC proliferation (B, open bars) compared with Sham
transduced control cells. Cell proliferation was assessed using MTT assay, and data are presented
as mean ± standard error of the mean (SEM) from three independent experiments. ERK2 in (A)
confirms equivalent lane loading. (C) 3-dimensional (3D) co-cultures with IUSCC-PC1 pancreatic
cancer cells (PCCs) (green) and HUVECs (red) transduced with a non-targeting control (endothelial
cell (EC) Sham) or JAK1 shRNA (EC shJAK1) shows that JAK1 knockdown in ECs suppresses PCC
and EC growth. Shown are representative brightfield and fluorescent images from three independent
experiments. Scale bars, 200 µm. (right) Fluorescence intensity quantification confirms that JAK1
knockdown in ECs suppresses PCC and EC growth in 3D co-cultures (hatched bars). Data are mean
± SEM from three independent experiments. *P-value (P) < 0.05, #P < 0.01.
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Figure 2.13: SB505124 and ruxolitinib alone do not inhibit PCC growth in single 3-
dimensional (3D) cultures. Treatment of single 3D cultures of IUSCC-PC1 cells with DMSO,
100 nM ruxolitinib (Rux), or 2 µM SB505124 (SB) results in no differences in proliferation.
blood vessels within the stromal compartment (Figure 2.14B). Moreover, intravenous
injection of tetramethylrhodamine (TRITC) conjugated dextran followed by intravital
imaging using two-photon confocal microscopy, demonstrated many dextran-positive
vessels (Figure 2.14C), confirming the presence of blood flow.
We next conducted an array analysis using KRC tumor-derived RNA to determine
if they exhibit a pro-angiogenic gene expression profile compared to RNA derived from
age matched WT murine pancreata. GO analysis revealed that KRC tumors exhibited
significant enrichment of pro-angiogenic processes compared to age matched WT
murine pancreata (Figure 2.15A and 2.15B). Increased expression of pro-angiogenic
genes in KRC tumors could arise as a consequence of their up-regulation in the
cancer cells. Therefore, we next evaluated KRC-derived PCCs for a pro-angiogenic
gene expression profile. Accordingly, we conducted a GO analysis of microarray
data comparing KRC PCCs with PCCs derived from KC tumors, which also express
oncogenic Kras, but retain Rb1 function and express low levels of pro-angiogenic
cytokines [114]. These KRC PCCs derived from KRC tumors also exhibited significant
enrichment of pro-angiogenic processes (Figure 2.16).
qPCR validated the arrays and confirmed that KRC tumors and PCCs expressed
relatively high levels of Ctgf, Cyr61, Egfr, Nrp2, Serpine1, Tgfbr1 and Vegfc mRNA
(Figure 2.17A and 2.17B). By contrast, Vegfa mRNA levels were similar in KRC
and KC cells, in agreement with the observation that oncogenic Kras, per se, can
up-regulate Vegfa mRNA expression [118].
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Figure 2.14: KRC murine PDACs (mPDACs) exhibit angiogenesis. (A) KrasLSL-G12D/+;
Rb1-/-; Pdx-1-Cre (KRC) mPDACs harbor endothelial cells (ECs) adjacent to CK19 positive cancer
cells in the collagen-rich stroma as evidenced by Masson’s Trichrome staining of serial sections.
Quantitation (right) of CD31 and Masson’s Trichrome staining shows that EC abundance and
stromal content increases from postnatal months 2 to 4. (B) CD31 positive vessels are also present
throughout KRC mPDACs. Shown in (A–B) are representative images from 5 KRC mice at each age.
Insets in (A–B) are magnified images of boxed areas. Scale bars, 50 µm. (C) Intravital microscopy
shows that KRC tumors have blood flow as evidenced by the abundance of dextran-positive (red)
vessels. Shown is a representative image from 1 of 2 KRC mice.
2.10 KRC tumors show superior enrichment and differential expression
of The Cancer Genome Atlas (TCGA) angiogenic gene signature compared
to KPC tumors
While we have shown that KRC mPDACs exhibit abundant angiogenesis, KPC
mice are classically hypovascular [35, 36]. KPC mice express oncogenic Kras and
mutant Trp53 in the pancreas, and they progress from preinvasive disease to invasive
and widely metastatic mPDAC with a median survival of 19 weeks [119, 120]. To
determine if tumors from either of these models is enriched in the human pro-angiogenic
gene signature identified from TCGA, GSEA was executed on array data from both of
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Figure 2.15: KRC tumors are enriched in angiogenesis related Gene Ontology (GO)
terms. (A-B) Gene Ontology (GO) analysis of differentially expressed genes (|Fold Change (FC)|
>= 2, P-value (P) < 0.01) in tumors from 2 month old KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC)
mice (A) or 4 month old KRC mice (B) compared to age matched wild type (WT) murine pancreas
shows that genes annotated to vasculature development, blood vessel development, blood vessel
morphogenesis, artery morphogenesis, and angiogenesis are significantly enriched (P < 0.01).
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Figure 2.16: KRC cells are enriched in angiogenesis related GO terms. Gene Ontology
(GO) analysis of differentially expressed genes (|Fold Change (FC)| >= 2, P-value (P) < 0.01) in
KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) cells compared to KrasLSL-G12D/+; Pdx-1-Cre (KC) cells
shows that genes annotated to vasculature development, blood vessel development, blood vessel
morphogenesis, and angiogenesis are significantly enriched (P < 0.01).
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Figure 2.17: Quantitative Polymerase Chain Reaction (qPCR) validation of angiogenic
genes up-regulted in KRC tumors and cells. (A-B) Quantitative Polymerase Chain Reaction
(qPCR) for the indicated mRNAs validates the array data, and confirms that Ctgf, Cyr61, Egfr, Nrp2,
Serpine1, Tgfbr1, and Vegfc are significantly increased in 2 month (A, gray bars) and 4 month old
(A, open bars) KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) tumors compared with their respective
littermate controls (A, wild type (WT), closed bars), and in KRC cells (B, open bars) compared
with KrasLSL-G12D/+; Pdx-1-Cre (KC) cells (B, closed bars). Data in (A-B) are mean ± standard
error of the mean (SEM). *P-value (P) < 0.05.
these models. Overall, 2 month KRC tumors from 2 month and 4 month old mice and
KPC tumors from 3 month old mice all show enrichment of the signature (family-wise
error rate (FWER) < 0.001) with normalized enrichment scores (NESs) of 2.08, 2.11,
and 1.87, respectively (Figure 2.18A-2.18C top).
Visual representation of the expression differences in heatmaps confirms this trend,
with 4 month KRC tumors showing the largest difference in expression of this signature
(Figure 2.18A-2.18C bottom). However, it is important to note that the 4 month group
would consist of tumors obtained only from the ∼10% of KRC mice that survived longer
than the median of 10 weeks. While GSEA uses a rank based method, application of
stringent cut offs for differential expression (FC >= 1.5, FDR < 0.05) indicates that
2 month KRC tumors, 4 month KRC tumors, and 3 month KPC tumors differentially
express 13, 43 and 0 genes from the 77 gene signature (77 mouse homologs to the 79
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Figure 2.18: KRC tumors show superior enrichment and differential expression of The
Cancer Genome Atlas (TCGA) angiogenic gene signature. (A) (top) Gene Set Enrichment
Analysis (GSEA) of 2 month KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) tumor array data shows
enrichment of The Cancer Genome Atlas (TCGA) angiogenic gene signature (normalized enrichment
score (NES): 2.08, family-wise error rate (FWER) < 0.001). (bottom) Heatmap of expression values
from the 2 month KRC tumor array data for TCGA angiogenic genes. (B) (top) GSEA of 4 month
KRC tumor array data shows enrichment of TCGA angiogenic gene signature (NES: 2.11, FWER
< 0.001). (bottom) Heatmap of expression values from the 4 month KRC tumor array data for
TCGA angiogenic genes. (C) (top) GSEA of 3 month KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre
(KPC) tumor array data shows enrichment of TCGA angiogenic gene signature (NES: 1.87, FWER <
0.001). (bottom) Heatmap of expression values from the 3 month KPC tumor array data for TCGA
angiogenic genes. (A-C) (bottom) (red = up-regulated; green = down-regulated).
differentially expressed angiogenesis genes between the Strong PDAC and Weak PDAC
groups). Therefore, while KPC tumors may display enrichment of the signature, none
of the angiogenic genes meet stringent criteria for differential expression.
2.11 TGF-β promotes angiogenesis indirectly
We next assessed the ability of CM from KRC cells to enhance the proliferation and
migration of murine SVEC4–10 ECs that are commonly used to study angiogenesis
pathways in vitro [121]. CM from three KRC derived PCCs markedly enhanced EC
proliferation and migration (Figure 2.19A), suggesting that KRC cells may secrete
factors that promote EC proliferation in vivo. Because TGF-β signaling activity was
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present in the Strong PDAC group, we conducted GSEA on KRC tumor and cell
array data and found enrichment of a TGF-β gene set in 2 month (Figure 2.19B) and
4 month KRC (Figure 2.19C) tumors as well as in KRC cells (Figure 2.19D) derived
from the tumors (Figure 3B). Additionally, enrichment of the TGF-β gene set was
found in 3 month KPC tumors (Figure 2.19E).
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Figure 2.19: KRC conditioned media (CM) enhances angiogenesis and TGF-β signaling
in ECs. (A) Compared with control media (black bars), conditioned media (CM) from three
KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) cell lines (purple, blue, or green bars) significantly
enhances endothelial cell (EC) proliferation (top) and migration (bottom). Data are mean ±
standard error of the mean (SEM). **P-value (P) < 0.01; *P < 0.05. (B-E) Gene Set Enrichment
Analysis (GSEA) shows that 2 month KRC tumors (B, normalized enrichment score (NES): 2.43,
family-wise error rate (FWER) < 0.001), 4 month KRC tumors (C, NES: 2.47, FWER < 0.001),
KRC pancreatic cancer cells (PCCs) (D, NES: 1.98, FWER < 0.001), and 3 month KrasLSL-G12D/+;
Trp53LSL-R172H/+; Pdx-1-Cre (KPC) tumors (E, NES: 2.44, FWER < 0.001) are enriched in genes
up-regulated by TGF-β. (F) CM from KRC cells markedly increases murine phosphorylated SMAD2
(p-SMAD2) and murine phosphorylated SMAD3 (p-SMAD3) levels in ECs, which is blocked by
SB505124 [2 µM]. Shown are representative immunoblots from three independent experiments.
The presence of TGF-β signaling does not seem to be unique to a specific GEMM
as nuclear and stromal murine phosphorylated SMAD2 (p-SMAD2) immunoreactivity
has been observed in KC, KRC, KrasLSL-G12D/+; Cdkn2aLoxP/LoxP; Pdx-1-Cre (KIC),
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and KPC mPDACs [114, 122]. Murine phosphorylated SMAD3 (p-SMAD3) immunore-
activity has also been demonstrated in KRC mPDACs [114, 122]. While only TGFB3
was up-regulated in the Strong PDAC group (FC 3.40, FDR 1.31E-10), both Tgfb2
(FC 3.50, FDR 0.046) and Tgfb3 (FC 4.15, FDR 0.006) were up-regulated in 4 month
KRC tumors, and all three ligands were up-regulated in KRC cells compared to KC
cells (Tgfb1: FC 1.52, FDR 0.001; Tgfb2: FC 3.05, FDR 0.0001; Tgfb3: FC 2.23,
FDR 0.0001). However, none of these were up-regulated in 3 month KPC tumors.
While TGF-β has been shown to induce SMAD2 phosphorylation, the nuclear
translocation of SMAD2/3/4, and SMAD transcriptional activity in KRC cells, KRC
cells are not growth inhibited by TGF-β in contrast to KC cells [114]. In 3D cultures,
TGF-β induces the proliferation of KRC cells, but both control and treated cells show
co-expression of p-SMAD2 and Ki67 (gene: Mki67) [114].
The pro-angiogenic actions of KRC CM could be due to direct effects of TGF-β
on ECs, or through the up-regulation of pro-angiogenic genes in the PCCs and cells
within the tumor microenvironment (TME). To explore whether TGF-β acts directly
on ECs, we next assessed the ability of CM derived from KRC PCCs to activate
canonical TGF-β signaling in SVEC4–10 ECs. Indeed, KRC derived CM increased
SMAD2 and SMAD3 phosphorylation in ECs, which was blocked by the TGF-β
receptor type-1 (gene: Tgfbr1) inhibitor, SB505124 (Figure 2.19F), pointing to TGF-β
pathway activation in ECs. However, SB505124 failed to block the ability of KRC
derived CM to stimulate EC proliferation or migration (Figure 2.20A), indicating
that TGF-β does not directly enhance angiogenesis. To determine if TGF-βs promote
pro-angiogenic gene expression in KRC cells, we suppressed TGF-β receptor type-1
signaling with SB505124, and assayed Ctgf, Wisp1, Cyr61, Pdgfa, and Vegfc, all of
which were elevated in the Strong PDAC group except PDGFA. SB505124 blocked
SMAD2 phosphorylation [114] and markedly suppressed the levels of all five mRNAs
(Figure 2.20B). This suggests that TGF-β can promote angiogenesis indirectly by
up-regulating pro-angiogenic genes in the PCCs.
2.12 STAT3 is required for EC activation by PCCs
Out of 25 cytokines assayed by multiplex enzyme-linked immunosorbent assay
(ELISA) in KRC CM, only CXCL1, CXCL5, MCP-1 (gene: Ccl2), GM-CSF (gene:
Csf2), VEGF-A (gene: Vegfa), and VEGF-C (gene: Vegfc) were readily detected
in KRC CM, and TGF-β increased the levels of the latter three (Figure 2.21A).
Importantly, TGF-β increased GM-CSF by 14.7-fold and VEGF-A by 42-fold, whereas
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Figure 2.20: TGF-β receptor type-1 inhibition does not block endothelial activation
but suppresses angiogenic gene expression in PCCs. (A) SB505124 [2 µM] does not prevent
KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) conditioned media (CM) from enhancing endothelial cell
(EC) proliferation (top) or migration (bottom). (B) SB505124 [2 µM] significantly attenuates the
levels of the indicated mRNAs in KRC pancreatic cancer cells (PCCs). Data in (A-B) are mean ±
standard error of the mean (SEM). **P-value (P) < 0.01; *P < 0.05.
IL6 (gene: Il6), a potent inducer of STAT3, was below the level of detection. All
six of the detectable factors are pro-angiogenic and activate STAT3, an oncogene
and survival factor that can be activated by many additional cytokines and growth
factors [123, 124], that has been implicated in promoting tumor angiogenesis [125]
and modulating the TME [126]. Additionally, STAT3 has been shown to be active in
the endothelium of KRC mPDACs and 59% of hPDAC tumors [114].
We next determined if PCC derived factors activate endothelial STAT3 by using
CM from KRC PCCs. CM robustly increased STAT3 phosphorylation (Figure 2.21B)
and STAT3 dependent transcription in ECs (Figure 2.21C), which was completely
blocked by the JAK1/2 inhibitor, ruxolitinib, or by silencing Stat3 in ECs with a
shRNA that suppressed STAT3 to undetectable levels (Figure 2.21C). Ruxolitinib and
Stat3 silencing also blocked the ability of CM to stimulate EC proliferation (Figure
2.21D). Together, these results suggest that KRC derived factors promote EC growth
through STAT3 dependent pathways.
2.13 Ruxolitinib suppresses mitogenic crosstalk between ECs and PCCs
We next co-cultured fluorescently-labeled SVEC4–10 ECs and KRC PCCs in a 3D
culture system [114]. Remarkably, PCC growth was enhanced in the co-culture model
compared with 3D cultures in which PCCs were cultured separately from ECs, and
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Figure 2.21: KRC CM stimulates EC proliferation through STAT3. (A) Enzyme-linked
immunosorbent assay (ELISA) shows the levels of the indicated cytokines in KrasLSL-G12D/+; Rb1-/-;
Pdx-1-Cre (KRC) conditioned media (CM) in the absence (open bars) or presence (closed bars)
of TGF-β. Data are mean ± standard deviation (SD) from two different cell lines. (B) KRC
CM markedly increases murine phosphorylated STAT3 (p-STAT3) levels in endothelial cells (ECs),
which is blocked by ruxolitinib [100 nM]. (C) KRC CM significantly enhances STAT3 luciferase
reporter activity in ECs (top), which is blocked by ruxolitinib [100 nM] or a Stat3 targeting shRNA.
Immunoblotting (bottom) shows the knockdown efficiency of Stat3 targeting shRNAs. ERK2 confirms
equivalent lane loading. Shown in (B-C) are representative immunoblots from three independent
experiments. (D) CM from KRC cells significantly enhances EC proliferation, but in the presence of
ruxolitinib ([100 nM], left) or in ECs transduced with a Stat3 targeting shRNA (right), CM fails to
enhance EC proliferation. Data in (C-D) are mean ± standard error of the mean (SEM). *P-value
(P) < 0.05, and **P < 0.01.
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this enhanced growth in co-culture was completely suppressed by ruxolitinib (Figure
2.22A, 2.22B). By contrast, ruxolitinib failed to inhibit the growth of either PCCs or
ECs when cultured separately (Figure 2.22B). Thus, ECs can enhance PCC growth
through an angiocrine mechanism, which is suppressible by targeting JAK1/2 with
ruxolitinib. Unlike ruxolitinib, inhibiting TGF-β receptor type-1 with SB505124 was
able to inhibit the growth of KRC cells when cultured alone [114].
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Figure 2.22: Ruxolitinib suppresses mitogenic crosstalk between ECs and PCCs. (A)
3-dimensional (3D) co-cultures of endothelial cells (ECs) (red) and KrasLSL-G12D/+; Rb1-/-; Pdx-1-
Cre (KRC) pancreatic cancer cells (PCCs) (green) shows that compared with vehicle (DMSO, left),
ruxolitinib ([100 nM], right) suppresses PCC growth. Shown are representative phase contrast and
fluorescent images taken on day 8. Scale bars, 200 µm. (A) Fluorescence intensity quantitation
shows that compared with 3D cultures in which ECs and PCCs are cultured independently (single
culture), culturing ECs and PCCs together (co-culture) in 3D significantly enhances PCC growth,
which is blocked by ruxolitinib (open bars). Data are mean ± standard error of the mean (SEM)
from three independent experiments. *P-value (P) < 0.05, and **P < 0.01.
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2.14 SB505124 attenuates PDAC growth and prolongs survival in KRC
mice
We next evaluated the impact of TGF-β receptor type-1 signaling blockade on
tumor growth and survival in the context of an intact immune system using KRC cells
in a syngeneic orthotopic model. Treatments began on day 10 after intra-pancreatic
PCC injection. By day 17, tumors in vehicle-treated mice had grown by 810%, whereas
in SB505124-treated mice, tumors had grown by 195% (Figure 2.23A). Overall, 100%
of vehicle-treated mice succumbed to disease by day 26 (Figure 2.23B). By contrast,
SB505124-treated mice survived as long as 50 days (Figure 2.23B). Additionally,
SB505124 treated tumors showed attenuated CD31 immunoreactivity (Figure 2.23C).
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Figure 2.23: SB505124 attenuates PDAC growth and prolongs survival in KRC mice.
(A) Quantitation shows that SB505124 (SB, white bars) significantly attenuated tumor volumes
compared to Vehicle (V, black bars). *P-value (P) < 0.031. (B) Kaplan-Meier survival curves
reveal that SB505124 significantly prolonged the survival of mice bearing KRC1017-derived (green
versus blue line, P = 0.026) and KRC1022-4–derived (red versus orange line, P = 0.007) tumors.
Horizontal line indicates 50% survival. (C) Vehicle-treated tumors (top) display abundant CD31
immunoreactivity, which is markedly attenuated in (bottom) SB505124-treated tumors. Shown are
representative images from 3 mice per group. Scale bars, 50 µm.
2.15 Ruxolitinib attenuates PDAC growth and prolongs survival in KRC
mice
Endothelial recruitment and growth is an important aspect of tumor biology,
including the progression of pre-malignant lesions to cancer [12]. KRC mice develop
acinar-to-ductal metaplasia (ADM) and PanIN lesions that rapidly and frequently
progress to mPDAC [117]. Moreover, lesion initiation and progression occurs in
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conjunction with the appearance of inflammatory infiltrates and increased cytokine
expression [117]. Therefore, we next used this GEMM to determine if inhibiting
JAK1/2 with ruxolitinib could act to impede angiogenesis and suppress PanIN pro-
gression and mPDAC growth. Accordingly, we administered ruxolitinib to KRC mice
at postnatal month 1, an age at which ADM, PanIN, and mPDAC are commonly
observed in the pancreas. After 3 weeks of therapy, we evaluated their pancreata
for extent and severity of disease. All vehicle-treated mice exhibited multiple foci
of ADM, PanIN, and mPDAC (Figure 2.24A) that occurred in conjunction with
strong, nuclear murine phosphorylated STAT3 (p-STAT3) immunoreactivity (Figure
2.24B). The cancer cells and ADM were proliferative as evidenced by the presence
of nuclear phosphorylated Histone H3 (p-Histone H3), and were surrounded by an
abundance of CD31 positive ECs (Figure 2.24B). Moreover, ECs in vehicle-treated
mice frequently harbored nuclear p-STAT3 (Figure 2.24C). Remarkably, the pancreata
of KRC mice receiving ruxolitinib were mostly normal, and only displayed small foci
of ADM (Figure 2.24A) that exhibited weak p-STAT3 immunoreactivity and markedly
attenuated proliferation, and were associated with few ECs (Figure 2.24B) in which
nuclear p-STAT3 immunoreactivity was markedly attenuated (Figure 2.24C).
Moreover, in a survival study, 100% of ruxolitinib-treated mice were alive and
healthy at postnatal week 14, with only one mouse succumbing at postnatal week 15
(Figure 2.24D). By contrast, all vehicle-treated mice succumbed by postnatal week
8.5 (Figure 2.24D). Therefore, ruxolitinib attenuates ADM progression to PanIN and
mPDAC, while suppressing angiogenesis and markedly prolonging survival in this
autochthonous model.
We next used the KPC GEMM to determine whether targeting JAK1/2 with
ruxolitinib suppresses PanIN progression and mPDAC growth in this model. We
administered ruxolitinib to KPC mice at postnatal month 3 when they often exhibited
ADM, PanIN, and mPDAC. After 3 weeks of therapy, pancreatic histology from vehicle
and ruxolitinib treated mice were similar (Figure 2.25A), and frequently exhibited
abundant ADM, PanIN and mPDACs, with many p-Histone H3 positive nuclei but
few CD31 positive ECs (Figure 2.25B). Therefore, ruxolitinib failed to suppress cancer
cell proliferation or mPDAC progression in KPC mice.
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Figure 2.24: Ruxolitinib attenuates PDAC growth and prolongs survival in KRC mice.
(A) Vehicle-treated mice display abundant lesions and murine PDAC (mPDAC), whereas ruxolitinib
treated pancreata are mostly normal and only display small foci of acinar-to-ductal metaplasia (ADM).
Shown are representative images from two mice per group. Right panels are high magnification
images of boxed areas. (B) Nuclear murine phosphorylated STAT3 (p-STAT3) (left) is abundant in
KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) mPDACs (top) and ADM (middle) in vehicle treated
mice, whereas ADM in ruxolitinib treated mice (bottom) have weak p-STAT3 immunoreactivity.
mPDACs and ADM in vehicle treated mice also have abundant endothelial cells (ECs) and are highly
proliferative as evidenced by the presence CD31 and phosphorylated Histone H3 (p-Histone H3)
immunoreactivity, respectively. ADM in ruxolitinib treated mice have few CD31 positive ECs, and
p-Histone H3 is mostly absent. (C) VE-cadherin (gene: Cdh5) positive ECs (green) in vehicle-treated
KRC mice harbor nuclear p-STAT3 (left, red, arrows), whereas ECs in ruxolitinib treated mice
lack nuclear p-STAT3 (right, arrowhead). All images were acquired using the same exposure time.
Scale bars in (A-C), 50 µm. (D) Kaplan-Meier analysis shows that compared to vehicle (red line),
ruxolitinib (blue line) significantly (P-value (P) = 0.018) prolongs survival of KRC mice. Dashed
line indicates that two ruxolitinib treated mice were alive beyond postnatal week 18.
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Figure 2.25: KPC mice do not benefit from Ruxolitinib. (A) Pancreata from vehicle and
ruxolitinib treated KrasLSL-G12D/+; Trp53LSL-R172H/+; Pdx-1-Cre (KPC) mice are similar, and
exhibit an abundance of lesions and murine PDAC (mPDAC). Right panels are high magnification
images of boxed areas. (B) mPDACs in vehicle and ruxolitinib treated KPC mice harbor highly
proliferative cancer cells, as evidenced by the presence of strong, nuclear phosphorylated Histone H3
(p-Histone H3) immunoreactivity, but few endothelial cells (ECs), as evidenced by the paucity of
CD31 immunoreactivity. Shown in (A-B) are representative images from two mice per group. Scale
bars, 50 µm.
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3 Discussion
While the adult vasculature is primarily quiescent, notable examples of physiologic
angiogenesis include wound healing or female reproductive processes [7, 8, 10–15].
Tumors, on the other hand, demonstrate pathologic angiogenesis, which often results
in abnormal and leaky vessels [8, 10–13, 15–17, 19, 21]. Angiogenesis is required for
tumor growth, as tumor fragments or cells placed in an avascular environment like a
rabbit cornea are growth inhibited unless they can attract new capillaries [7]. Because
both angiogenesis inducers and inhibitors can be active at the same time, tumors often
undergo what is called an ‘angiogenic switch’ when the number of inducers begin to
dominate [7, 8, 20]. Much effort has been spent on identifying the critical inducers or
inhibitors in order to synthesize the endogenous inhibitors for use as anti-angiogenic
drugs or to develop drugs that can block the inducers [127]. Known inducers include
VEGFs, fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs),
angiopoietins (ANGPTs), TGF-β, and cytokines like IL-8 (gene: CXCL8) [81, 128],
while inhibitors include interferons (IFNs), thrombospondins (TSPs), endostatin (gene:
COL18A1) (endostatin), and angiostatin (gene: PLG) (angiostatin) [7, 127].
PDACs are often not considered to be angiogenic tumors or to be good candidates
for anti-angiogenic therapy because of their lack of vasculature compared to a nor-
mal human pancreas [35, 36]. However, many tumor types display reduced MVDs
compared to their normal tissue counterparts, including lung, mammary, renal cell,
and colon carcinomas [37, 129]. Additionally, we have shown that MVD can be quite
heterogeneous among PDAC tumors with 28%, 37%, and 35% of samples showing
strong, moderate, and weak staining of the EC marker CD31. It is well established
that MVD is useful as a prognostic marker for many cancers, including malignant
melanoma, non-small-cell lung, genitourinary, esophageal, and gastrointestinal cancers
[37], and one [40] of two [43] PDAC studies have shown that increased MVD is
associated with decreased patient survival.
However, while MVD can account for the presence of blood vessels in tumors, it
does not measure the rate of ongoing angiogenesis in the tumor. To measure that, other
methods must be utilized such as dual staining for both endothelial and proliferative
markers. Such methods have identified tumor types that are more angiogenic, such as
glioblastoma and renal cell cancer, but there is still great variability in the angiogenic
rate among different samples from these tumor types and all tumor types tested
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(glioblastoma, renal cell, colon, breast, lung, prostate) have shown angiogenic rates
above that of normal tissue, which usually is undetectable [129]. This confirms the
importance of angiogenesis for all tumor growth.
To help identify important angiogenic pathways in PDAC, we analyzed RNA-Seq
data from known angiogenic genes in TCGA and found that 35%, 47%, and 18%
of PDAC samples demonstrate a Strong, Moderate, and Weak pro-angiogenic gene
signature. While immunohistochemical analysis of TCGA samples is not possible,
the mean and median levels of CD31 protein expression were higher in the PNET
and Strong PDAC groups as compared to the Moderate and Weak PDAC groups,
though there was significant variability within the samples of each group. While this
classification was made using RNA-Seq technology, it would be interesting to see
if this gene expression signature would correlate with protein expression as mRNA
levels do not always correlate with protein expression levels [130]. Importantly, there
are a number of pancreatic cancer studies that have utilized mass spectrometry to
identify overexpressed proteins [131–133]. Additionally, the proteomic equivalent
of TCGA, Clinical Proteomic Tumor Analysis Consortium (CPTAC) has released
Funding Opportunity Announcements (FOAs) at the end of 2015 to support efforts
that would explore the connections between cancer proteomes and cancer genomes,
and it includes protocols for collecting PDAC samples. While there are many examples
of the use of individual proteins as cancer biomarkers in clinical practice, the clinical
use of a panel of molecular markers is currently limited to genomic based assays like
Oncotype DX, MammaPrint, Prosigna, and Endopredict for breast cancer [134, 135].
TCGA dataset consisted of 8 PNET samples, which afforded a great opportunity
to compare and contrast these two pancreatic tumor types in regards to angiogenic
gene expression. In contrast to PDAC tumors, PNETs confer a better prognosis
[24], exhibit abundant vasculature [88, 136], and respond to anti-VEGF directed
therapy, including bevacizumab and multi-kinase inhibitors like sunitinib, sorafenib,
and pazopanib, albeit with response rates of only 9-22% [88]. PNETs displayed a
median of 19 non-silent somatic gene mutations while PDACs had a median of 47
non-silent somatic mutations. As expected, PDACs displayed frequent mutations or
deletions in the KRAS, TP53, CDKN2A, or SMAD4 genes. While only 3 of the 8
PNET samples had DNA-Sequencing (DNA-Seq) data, none displayed mutations in
genes commonly altered in PNETs, such as the chromatin modifiers MEN1, DAXX
and ATRX, or mTOR pathway members [25, 137]. Two, however, displayed mutations
in a different chromatin modifier, KMT2D. While the Weak PDAC group had a higher
median number of mutations (64) than the Strong PDAC group (40), there was no
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difference in the mutation rate of any individual known angiogenic gene between the
two groups. While PDAC groups with differing amounts of structural chromosomal
variation have been described before [28], this is the first time such a difference has
been associated with the expression of an angiogenic gene signature.
Differential expression analysis comparing the PNET or Strong PDAC group to
the Weak PDAC group revealed that the Strong PDAC group up-regulated 79 of 129
angiogenic genes while the PNET group up-regulated 41 of 129 angiogenic genes. Of
these, 48 were unique to the Strong PDAC group, 10 were unique to the Weak PDAC
group, and 31 were common between them.
While comparing PNETs to a PDAC subgroup may not be ideal, such compar-
isons have been done previously even when gene expression information on multiple
pancreatic tissue types was available [100]. For example, Lowe et al. obtained gene
expression information from PNETs, PDACs, normal pancreatic tissue, PCC lines,
primary human cultures of pancreatic duct cells, and purified normal human islets
[100]. Instead of comparing PNETs to normal human islets and PDAC tumors or
PCC lines to normal pancreatic tissue (representing acinar cells) or pancreatic duct
cells, Lowe et al. utilized the SAM algorithm to identify genes differentially expressed
in one group as compared to all these other groups [100]. This analysis identified
up-regulation of PNET genes like SCG2 (FC: 27.44), TTR (FC: 5.07), INSM1 (FC:
6.65), PCSK2 (FC: 20.44), QPCT (FC: 13.61), and PTPRN2 (FC: 6.81). For these
same genes, our TCGA PNET vs. Weak PDAC comparison showed the following
fold changes: SCG2 (FC: 65.37, FDR: 6.87E-05), TTR (FC: 51.23, FDR: 0.0014),
INSM1 (FC: 43.76, FDR: 05.35E-08), PCSK2 (FC: 73.22, FDR: 5.86E-05), QPCT
(FC: 15.03, FDR: 2.86E-05), and PTPRN2 (FC: 10.53, FDR: 5.35E-14), suggesting
that such a comparison can correctly identify genes commonly up-regulated in PNETs
[100, 138]. Because PNETs often arise from different cells within the islet to produce
insulinomas vs. glucagonomas vs. somatostatinomas, one might also argue that normal
human islets are not specific enough of a comparator for PNETs. Similarly, the cell
of origin for PDAC tumors is still debated, and though PDACs appear ductal like,
there is a large body of evidence that they originate from acinar cells instead of ductal
cells [139]. Therefore, our choice to compare PNETs and one PDAC subgroup to
another PDAC subgroup is befitting considering the uncertainty around what is the
appropriate comparator and given the data available to us in TCGA.
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Both SCG2 and ISL1 are also angiogenic genes that were uniquely up-regulated in
PNETs. SCG2 can produce a peptide, secretoneurin, that can stimulate EC migration,
induce capillary tube formation in a matrigel assay, and induce neovascularization in
a mouse cornea model [140, 141]. ISL1 overexpression has also been shown to enhance
the survival, migration, and the tube forming ability of HUVECs [142].
Interestingly, commonly up-regulated genes included all three of the VEGF re-
ceptor genes: FLT1, KDR, and FLT4. Additionally, both groups up-regulate other
less well known angiogenic genes such as APOLD1, which encodes for vascular early
response gene (VERGE) [143]; GPLD1, which is an enzyme that can cleave glycosyl-
phosphatidylinositol (GPI) anchored proteins like Cripto-1 (gene: TDGF1), which
then functions as a chemoattractant for ECs [144]; BMPER, an activator of FGF
signaling [145]; and SFRP1, a pro-angiogenic molecule only expressed during the
formation of neovessels and no longer present after vascular maturation [146]. PNETs
and the Strong PDAC group also up-regulate many genes which traditionally have
played a role in the nervous system, but now have been shown to also operate in the
vascular system such as neurexin genes NRXN1 and NRXN3, ROBO4, SLIT2, and
SEMA3E [147–151]. In regards to FGF signaling, both also up-regulate FGFR1, but
only PNETs up-regulate FGF9 while also significantly down-regulating FGFR2 (FC:
-17.60 , FDR: 3.17e-14). While the significance of the FGFR2 down-regulation in
PNETs is unknown, such down-regulation has also been reported in prostate cancer
[152] and use of a dominant negative FGFR2 in a prostate cancer mouse model has
resulted in a neuroendocrine-like phenotype [153]. Neuroendocrine differentiation is a
common phenotypic change observed in prostate cancer [154] and thus, low FGFR2
may be a characteristic of neuroendocrine differentiation.
The Strong PDAC group, on the other hand, expresses even more unique angiogenic
genes, including pro-angiogenic collagens and integrins like COL15A1, COL4A3,
ITGAV, ITGB1 and integrin interacting proteins like GPR124 (gene: ADGRA2)
[155–157]. This group also overexpresses genes from the angiopoietin–Tie system,
including ANGPT1, TEK, and TIE1; hypoxia related genes HIF1A and EPAS1,
and TGF-β family members, including TGFBR1, TGFBR2, and ACVRL1. Overall,
PNETs and PDACs have distinct angiogenesis gene signatures, which might explain
their differential response to existing anti-angiogenic treatments.
Further investigation of the TGF-β signaling pathway identified 12 of the 79
angiogenic signature genes as known downstream targets, and an additional 50 TGF-β
responsive genes were up-regulated in the Strong PDAC group. In line with this, the
Strong PDAC group was less likely to have a mutation or deletion in SMAD4 (13%) as
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compared to the Moderate (37%) or Weak (42%) PDAC groups, and SMAD4 protein
expression correlated with CD31 protein expression (r = +0.72, P < 0.01) both in
TCGA and a TMA. While TGF-β can inhibit cell proliferation, it also plays many
other roles in embryogenesis, differentiation, apoptosis, motility, invasion, extracellular
matrix production, angiogenesis, and the immune response [158, 159]. In tumor
progression, TGF-β’s tumor suppressor roles become inactivated, thus turning it
into a tumor promoting molecule [158, 159]. While this inactivation might occur
via mutations or deletions of genes in the canonical TGF-β pathway like SMAD4,
we have also shown that deletion of Rb1 can produce this effect in the context of
intact canonical TGF-β signaling [114]. Therefore, when we highlight that the Strong
PDAC subgroup has active TGF-β signaling with an intact SMAD4 axis, we do so to
emphasize that TGF-β’s angiogenic role likely occurs through the canonical pathway
and that inhibition of this angiogenic axis through TGF-β inhibition could be useful
in this subgroup. Therefore, it is still possible that TGF-β inhibition could be useful
in the other subgroups due to other active TGF-β tumor promoting properties in
those samples.
Additional comparisons of differentially expressed genes between the Strong and
Weak PDAC groups also identified enrichment of inflammatory gene sets, including
up-regulation of 40 JAK/STAT signaling genes. In line with this, 3D co-culturing of
human PCCs and human ECs showed activation of p-JAK1 (Figure 3.1A) and use of
CM from human PCCs on human ECs or from human ECs on human PCCs revealed
that this increase in p-JAK1 occurred in ECs alone (Figure 3.1B). Additionally, CM
from both human cell types could increase p-SMAD levels in the other cell type (Figure
3.1B). Subsequently, targeting both TGF-β signaling with a TGF-β receptor type-1
inhibitor, SB505124, and JAK/STAT signaling with a JAK1/2 inhibitor, ruxolitinib,
blocked human PCCs and human ECs from stimulating the proliferation of one another
in a 3D co-culture system (Figure 3.1A). Similarly, ruxolitinib alone was able to prevent
murine ECs from stimulating the proliferation of KRC PCCs in a 3D co-culture system
(Figure 3.1C). However, in the mouse system, even though KRC CM was shown to
stimulate the proliferation of murine ECs through p-STAT3, this proliferation of ECs
was not seen in the 3D culture system. Therefore, in both human and murine cells,
the more dramatic proliferation occurred in PCCs through a mechanism involving
angiocrine signaling from ECs to PCCs. It is possible, however, that PCCs could
induce this signaling by first stimulating the ECs to release proliferative growth factors.
To translate these findings to an in vivo system, KRC and KPC mice were given
a course of ruxolitinib at a point when ADM, PanIN, and mPDAC lesions were
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Figure 3.1: Ruxolitinib alone blocks murine SVEC4-10 EC + murine PCC proliferation
while Ruxolitinib and SB505124 together block human vascular endothelial cell (HU-
VEC) + human PCC proliferation. (A) 3-dimensional (3D) co-culturing of human pancreatic
cancer cells (PCCs) with human endothelial cells (ECs) leads to proliferation of both cell types,
and this proliferation is blocked by treatment with SB505124 (SB) [2 µM]+Ruxolitinib (Rux) [100
nM] or shRNA knockdown of JAK1 in ECs. 3D co-culturing of human PCCs with ECs leads to
phosphorylation of JAK1 and this is also blocked by SB505124 (SB) [2 µM]+Ruxolitinib (Rux) [100
nM] treatment. (B) Applying conditioned media (CM) from human PCCs to human ECs leads to
activation of phosphorylated JAK1 (p-JAK1) and phosphorylated SMAD2/3 (p-SMAD2/3) whereas
applying CM from human ECs to human PCCs only leads to activation of p-SMAD2/3. (C) 3D
co-culturing of murine KrasLSL-G12D/+; Rb1-/-; Pdx-1-Cre (KRC) PCCs with murine ECs leads
to the proliferation of KRC PCCs, and this is blocked by Ruxolitinib [100 nM] treatment. (D)
Applying CM from murine KRC PCCs to ECs leads to the proliferation of ECs, and this is blocked
by treatment with Ruxolitinib [100 nM] or shRNA knockdown of Stat3 in ECs. CM from KRC PCCs
also leads to murine phosphorylated STAT3 (p-STAT3), murine phosphorylated SMAD2 (p-SMAD2),
and murine phosphorylated SMAD3 (p-SMAD3) activation in ECs. Application of CM from KRC
PCCs to ECs along with treatment of SB505124 [2 µM] blocks p-SMAD2 and p-SMAD3 activation in
these cells, but it does not prevent the CM from stimulating proliferation of the ECs. CM from KRC
PCCs contains CXCL1, CXCL5, MCP-1 (gene: Ccl2), GM-CSF (gene: Csf2), VEGF-A (gene: Vegfa),
and VEGF-C (gene: Vegfc); TGF-β treatment [0.5 nM] of KRC PCCs increases the levels of the
latter three. TGF-β treatment [0.5 nM] of KRC PCCs leads to increased SMAD2 phosphorylation
and transcription of the pro-angiogenic Ctgf, Cyr61, Egfr, Nrp2, Serpine1, Tgfbr1 and Vegfc genes in
these cells, and this is blocked by treatment with SB505124 [2 µM].
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present. KRC mice demonstrated an improvement in survival and delayed mPDAC
progression while KPC mice were refractory to treatment. Gene expression analysis
of KRC and KPC tumors revealed significant expression of the previously identified
TCGA angiogenic signature in the KRC model but not in the KPC model, giving
a possible explanation for the refractoriness of KPC mice. However, some patient
samples from the Strong PDAC group have mutations in both the KRAS and TP53
genes, suggesting it is not that simple of an explanation. While Kras and Trp53 are
initiating mutations in the KPC model, different mice acquire distinct mutations
during mPDAC progression and this results in more heterogeneous gene expression in
KPC tumors than what we have observed in KRC tumors. Because PANC-1 cells also
have a TP53 mutation, perhaps KPC mice and ‘KP’ patients in the Strong PDAC
group would only benefit from the dual therapy treatment regimen. Overall, we have
uncovered an important angiocrine mechanism in PDAC that could be targeted using
dual TGF-β receptor type-1 and JAK1/2 inhibitors in the 35% of patients with a
Strong pro-angiogenic gene signature.
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4 Conclusion
Over the last 20 years, efforts in targeting angiogenesis in cancer have focused
almost entirely on the pro-angiogenic molecule VEGF-A, and there are now several
FDA approved drugs for various cancers [10, 13, 16, 17, 21, 160]. In reality, despite
very convincing pre-clinical data, some cancers are completely resistant to such therapy,
such as PDAC, or develop resistance over time [10, 13, 16, 17, 20, 21, 160]. This
suggests that other angiogenic pathways that we have yet to address are involved.
Our analysis of TCGA RNA-Seq data from both PNET and PDAC tumors
identified angiogenic pathways and genes unique to each tumor type. While we have
successfully targeted the common TGF-β and JAK/STAT signaling pathways in pre-
clinical PDAC models in this study, our analysis has identified many new uncommon
and unexplored molecules in PNET or PDAC angiogenesis, such as SCG2 and ISL1
in PNETs, collagens and integrins in PDACs, or APOLD1, GPLD1, and SFRP1 in
both PNETs and PDACs to name only a few. While this study has confirmed the
importance of VEGF signaling in pancreatic cancer angiogenesis, it is clear that many
other players are also involved and that successful targeting of angiogenesis in PDAC
will entail targeting several of them simultaneously in the right patients.
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5 Methods
5.1 Immunohistochemistry (IHC)
5.1.1 Human tissue microarray (TMA)
A paraffin-embedded hPDAC TMA was obtained from the Tissue Procurement
and Distribution core at the Indiana University Simon Cancer Center, and 4 µm
sections were prepared. Approval for the acquisition of all human tissue was granted
by the Institutional Review Board (IRB) at the Office of Research Administration at
Indiana University.
IHC was performed as described [114]. For the CD31 analysis, a CD31 (Abcam)
antibody was used at a dilution of 1:200. For the CD31 and SMAD4 analysis, SMAD4
(Leica Biosystems, Buffalo Grove, IL) and CD31 (BD Biosciences, Franklin Lakes,
NJ) antibodies were used. Quantitation was performed using positive pixel count in
Aperio Imagescope software.
5.1.2 KRC or KPC tumors
IHC was performed as described [114]. In brief, pancreata from KRC or KPC
mice were harvested at the indicated time points, fixed in 10% formalin overnight
and embedded in paraffin. 4 µm sections were prepared using a HM355S microtome
(Thermo Scientific). After deparaffinization and tissue rehydration, antigen retrieval
was performed with antigen unmasking solution (Vector Labs, Burlingame, CA)
or EDTA. A CD31 (Abcam) antibody was used at a dilution of 1:200, a CK19
(DSHB) antibody was used at a dilution of 1:10, a p-STAT3 antibody was used at
a dilution of 1:200, and a p-Histone H3 antibody was used at a dilution of 1:200.
Immunohistochemical detection was using biotinylated secondary antibodies, and
a NOVA RED detection kit (Vector Labs). Masson’s Trichrome (Richard-Allan
Scientific) was performed according to manufacturer’s recommendations.
For quantification, images were obtained at 20x magnification from 5 different
fields using 3 mice using an Olympus BX60 microscope and a QImaging ExiBlue
camera. Overall positive pixel intensity was determined using ImageProPlus v7.0
(Media Cybernetics). Quantitation data are presented as mean pixel intensity ±
standard error of the mean (SEM).
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5.2 Hierarchical clustering
5.2.1 TCGA angiogenic gene signature
Establishment of signature
The RNA-Seq RSEM [161] normalized reads and the raw count reads from TCGA
pancreatic cancer dataset (abbreviated PAAD in TCGA), which has gene expression
information on 88 samples from 85 patients: 85 tumor samples and 3 matched normal
samples, was downloaded on June 6th, 2014 from http://cancergenome.nih.gov/. This
dataset consists of 76 PDAC tumors, 3 colloid (mucinous non-cystic) carcinomas, and
6 samples of unknown histological type. For the analysis, we used all 85 tumor samples,
for a total of 85 expression profiles. 580 Human UniProt ids that were directly or
indirectly annotated to the GO [162] term angiogenesis (GO:0001525) were mapped to
389 Entrez gene ids via use of the BioMart [163, 164] Bioconductor [165, 166] package,
384 of which had expression values in TCGA dataset.
Hierarchical clustering was performed in R by applying a Pearson correlation
distance and average linkage function to the normalized RSEM values of the 384
genes for the 85 tumor samples, and then scaling and graphing the result using the
heatmap.2 function of the gplots R package. Because the resulting dendrograms
indicated there was a subset of patients with up-regulated angiogenesis genes, we
zoomed in on a dendrogram leaf of 129 genes, and then reclustered the data as follows.
The normalized RSEM values for the 129 genes for the 85 tumor samples were first
centered and scaled in R, and then hierarchical clustering on the rows was done using
the Pearson correlation distance and average linkage function while column clustering
was done using the Euclidean distance and complete linkage function. After graphing
with heatmap.2, the result showed 3 distinct clusters of patients, which we assigned
as having a “Strong” (n=10), “Moderate” (n=59), or “Weak” (n=16) angiogenesis
signature.
Validation
The RNA-Seq RSEM [161] normalized reads and the raw count reads from TCGA
pancreatic cancer dataset (abbreviated PAAD in TCGA), which has gene expression
information on 183 samples from 178 patients: 179 tumor samples (2 samples from 1
patient) and 4 matched normal samples, was downloaded on December 31, 2014 from
http://cancergenome.nih.gov/. This dataset consists of 135 PDAC tumors, 14 PDAC
tumors with varying subtype designations, 4 colloid (mucinous non-cystic) carcinomas,
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1 undifferentiated carcinoma, 8 PNETs, and 16 samples of unknown histological type.
For the analysis, we only focused on the 135 PDAC tumors and the 8 PNETs, for a
total of 143 expression profiles.
Using the previously determined 129 gene angiogenic signature, hierarchical clus-
tering was performed in R by centering and scaling the normalized RSEM values of
the 129 genes for the 143 tumor samples, and then clustering the rows using a Pearson
correlation distance and average linkage function and the columns using a Euclidean
distance and complete linkage function. The centered and scaled expression values
were graphed as a heatmap with red representing up-regulated genes and green down-
regulated genes in combination with the associated row and column dendrograms using
the heatmap.2 function of the gplots R package. The 8 PNET samples all clustered
together, and the PDAC tumors were assigned to a “Strong” (n=47), “Moderate”
(n=64), or “Weak” (n=24) PDAC angiogenic group based on the remaining clustering
results.
5.2.2 TGF-β responsive genes
For the TGF-β profile, 192 Human Genome Organisation (HUGO) gene names
annotated to the “TGFB UP.V1 UP” gene set, which represents genes up-regulated
in a panel of epithelial cell lines by TGF-β1 (gene: TGFB1), were obtained from
the GSEA Molecular Signatures Database. 190 of these had associated HUGO Gene
Nomenclature Committee (HGNC) ids, which were then mapped to 190 Entrez gene
ids using the Homo sapiens gene info file available from the National Center for
Biotechnology Information (NCBI) FTP site. 2 of the genes that were already a part
of the 129 angiogenic signature were removed and another 2 did not have associated
TCGA RNA-Seq information, bringing the final list used for clustering to 186 genes.
In the clustering, the same samples and parameters were used as in the angiogenesis
profile except that the sample columns were not clustered but instead placed in the
same order as they appear in the angiogenesis profile. 70 of the 186 TGF-β responsive
genes were differentially expressed (“Strong” vs. “Weak”, |FC| ≥ 1.5, FDR < 0.05).
5.2.3 Positive or negative regulation of the inflammatory response
For the inflammatory profiles, 130 or 142 human UniProt ids that were di-
rectly or indirectly annotated to the “positive regulation of inflammatory response”
(GO:0050729) or the “negative regulation of inflammatory response” (GO:0050728)
GO terms, respectively, were mapped to 93 or 92 Entrez gene ids, respectively, via
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the use of the BioMart [163, 164] Bioconductor [165, 166] package. Both of these lists
had 6 genes that were also a part of the original 129 angiogenic signature, and so
these genes were removed, leaving a final list of 87 and 86 genes. 85 out of 87 positive
regulators and 81 out of 86 negative regulators had associated TCGA RNA-Seq
information. Clustering was performed separately on each list using the same samples
and parameters as before except that the sample columns were not clustered, but
instead placed in the same order as they appear in the angiogenesis profile. 35 out of
the 85 positive regulators and 33 out of the 81 negative regulators were differentially
expressed (“Strong” vs. “Weak”, |FC| ≥ 1.5, FDR < 0.05).
5.3 TCGA survival and treatment analysis
Survival or treatment information for PDAC and PNET patients was downloaded
on December 31, 2014 from http://cancergenome.nih.gov/. All patients had associated
clinical information on days to death or days to last follow-up (censored). Overall
survival for the 8 PNET, 34 Stage IIB PDAC, and 15 Stage IIB PDAC patients was
plotted using a Kaplan-Meier curve.
5.4 Differential expression
Differential expression analysis between the Strong and the Weak PDAC groups
as well as the PNET and Weak PDAC groups was carried out using DESeq [101] on
the raw count data. For the full dataset, 5,460 out of 20,531 genes are differentially
expressed between the Strong and the Weak PDAC groups (|FC| ≥ 1.5, FDR < 0.05),
with 79 of them belonging to the 129 angiogenic gene signature, while 6,166 out of
20,531 genes are differentially expressed between the PNET and Weak PDAC groups
(|FC| ≥ 1.5, FDR < 0.05), with 50 of them belonging to the 129 angiogenic gene
signature.
5.5 Principal Component Analysis (PCA)
PCs of the 129 expression values from the 143 samples were calculated using the
prcomp function in R with options set to center and scale the data. 2 PCs account for
38% of the variance while 3 PCs account for 46% of the variance. The first two PCs
were graphed using ggplot while the first three PCs were graphed using the plot3d
function of the rgl package.
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5.6 GeneMANIA
To assess angiogenesis gene interactions, we used GeneMANIA [102]. The angio-
genesis genes unique to PNETs (10), unique to the Strong PDAC group (48), or genes
that were common to both (31) were analyzed using GeneMANIA’s pathway datasets.
Any genes that were not directly connected were removed from the resulting network.
5.7 Mutation/copy number analysis
The curated mutation mutation annotation format (MAF) file (v.1.2.0) was down-
loaded on December 31, 2014 and included information from 98 PDAC cases and 3
PNET cases. The mutation calls are provided by the Broad Institute of MIT and
Harvard, a genome sequencing center (GSC) for TCGA, and their pipeline for making
the calls has not yet been distributed publicly or published for the pancreatic cancer
dataset. Silent mutations were removed. Then, a matrix of genes and samples was
built with each gene being coded as 1 (non-silently mutated), 0 (silently mutated or
not mutated) or NA (no data available). Therefore, multiple non-silent mutations
in a gene would only be counted once per gene. R was used to plot the mutation
profiles of the samples in the same order as they appear in the angiogenesis cluster
analysis. Significant differences in mutational frequencies were determined using a
Fisher’s exact test. P < 0.05 is considered statistically significant.
PDAC TCGA copy number data (level 4) was downloaded from the April 2, 2015
Broad GDAC Firehose GISTIC analysis run [167, 168]. The
all thresholded.by genes.txt file was used, which classifies genes as having a copy
number of −2 (deep loss, possibly a homozygous deletion), −1 (shallow loss, possibly
a heterozygous deletion), 0 (diploid), 1 (low-level amplification), or 2 (high-level
amplification). Of the PNET and PDAC samples, all 8 PNETs and 134 of 135 PDACs
samples had copy number data. R was used to plot copy number profiles in the same
order as in the angiogenesis cluster analysis. For combining SMAD4 mutation and
deletion frequency, we used 97 PDAC samples that had both mutation and copy
number data, with 40, 38, and 19 samples belonging to the Strong, Moderate, and
Weak PDAC groups, respectively. Frequencies of samples with a mutation or deep
deletion in SMAD4 were compared among the groups using a Fisher’s exact test, with
P < 0.05 considered significant.
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5.8 Ingenuity Pathway Analysis (IPA)
The 79 of 129 differentially expressed angiogenic genes between the Strong and
Weak PDAC groups (FC ≥ 1.5, FDR < 0.05) was subjected to Ingenuity Pathway
Analysis (IPA)’s Upstream Regulator Analysis tool to identify TGF-β as a major
upstream regulator of 17 of the 79 genes.
5.9 Protein expression analysis
Normalized RPPA values were downloaded from TCGA PDAC dataset on De-
cember 31, 2014 from http://cancergenome.nih.gov. Of the 135 PDAC and 8 PNET
samples used in the hierarchical clustering, 85 PDAC and 2 PNET samples had protein
expression information. CD31 and SMAD4 protein expression values for the 85 PDAC
and 2 PNET samples were used for plotting or calculating the correlation.
5.10 Gene Set Enrichment Analysis (GSEA)
5.10.1 Transplant rejection and inflammatory response gene sets for Strong
PDAC vs. Weak PDAC
Using the GSEAPreranked tool, GSEA version 2.2.0 was run on a ranked list of
genes that were sorted according to their fold change differences between the Strong
and Weak PDAC groups [169, 170]. This analysis identified the transplant rejection
and inflammatory response gene sets as being highly enriched.
5.10.2 TCGA angiogenic gene set for Genetically Engineered Mouse Model
(GEMM) tumors vs. wild type (WT)
Normalized, log2-transformed array data from the 2 month KRC tumors, 4 month
KRC tumors, and 3 month KPC tumors and age matched WT controls were prepared
in GSEA format [169]. A custom chip file that mapped probesets from the Agilent
SurePrint G3 Mouse GE 8x60K whole mouse genome microarray to HUGO gene
symbols was generated. Using version 2.1.0 (KRC and matched WT) or 2.2.0 (KPC
and matched WT) of the command line jar application, the array data was compared
against the 79 differentially expressed angiogenesis genes (Strong vs. Weak PDAC)
from the 129 TCGA angiogenesis gene signature.
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5.10.3 TGF-β gene set for GEMM tumors vs. WT or KRC cells vs. KC
cells
Normalized, log2-transformed array data from the 2 month KRC tumors, 4 month
KRC tumors, KRC cells, KC cells, and 3 month KPC tumors and age matched
WT controls were prepared in GSEA format [169]. A custom chip file that mapped
probesets from the Agilent SurePrint G3 Mouse GE 8x60K whole mouse genome
microarray or the Agilent Whole Mouse Genome 4x44K microarray to HUGO gene
symbols was generated. Using version 2.1.0 (KRC and matched WT) or 2.0.13 (KRC
or KC cells) of the command line jar application, the array data was compared
against the PLASARI TGFB1 TARGETS 10HR UP gene set [171], which represents
‘Genes up-regulated in mouse embryonic fibroblasts (MEF) cells upon stimulation
with TGF-β1 [GeneID=7040] for 10 hours’.
5.11 JAK/STAT heatmap
145 genes involved in JAK/STAT signaling were obtained from the GSEA
KEGG JAK STAT SIGNALING PATHWAY gene set. The differentially expressed
FCs and FDRs for these genes were isolated from the differential expression analysis
comparing the Strong and Moderate PDAC groups to the Weak PDAC group. 45/145
genes were differentially expressed in at least one of these comparisons (|FC| >= 1.5,
FDR < 0.05) and the FCs were graphed in a heatmap using the heatmap.2 func-
tion of the gplots R package with red representing up-regulation, green representing
down-regulation, and gray representing not differentially expressed.
5.12 Cell lines and conditioned media (CM)
5.12.1 Human
PANC-1 (CRL-1469) PCCs were from American Type Culture Collection (ATCC).
The IUSCC-PC-1 cell line was established from a patient-derived orthotopic xenograft
in an athymic mouse [122]. IUSCC-PC-1 cells were authenticated, and confirmed to be
human and free of pathogens and other cell types by IDEXX Bioresearch (St. Louis,
MO). By sequencing, the cell line harbored a KRAS mutation (KRASG12D/+) but lacked
SMAD4 mutations, and readily formed tumors in nude mice. HUVEC (CRL-1730) ECs
were from ATCC. PCCs were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
with 1% antibiotic (100 units/ml penicillin; 100 mg/ml streptomycin) and 5% fetal
bovine serum (FBS). HUVECs were cultured in EGM-2 medium (Lonza, Walkersville,
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MD). HUVECs were transduced with lentivirus containing JAK1 targeting shRNAs
or a non-targeting control shRNA from Thermo Fisher (Waltham, MA) as described
[142].
5.12.2 Mouse
KRC cells were generated using standard cell isolation and culture procedures as
described [114, 117]. SVEC4–10 ECs were obtained from ATCC (CRL-2181). ECs
were cultured in DMEM supplemented with 1% antibiotic (100 units/ml penicillin; 100
mg/ml streptomycin) and 10% FBS. For CM, KRC cells were seeded in 10 cm tissue
culture plates (BD Falcon). 72 hours post-serum starvation, media was collected,
centrifuged and filtered through a 0.22 µm syringe filter.
5.13 3-dimensional (3D) culture
3D culturing was done as described [114]. PCCs and ECs were fluorescently-labeled
before culturing in 3D. PCCs were transduced with an eGFP lentiviral construct
(Clontech), and ECs were labeled using the PKH26 red fluorescent cell linker kit per
the manufacturer’s recommendations (Sigma-Aldrich). 3,000 PCCs or 6,000 ECs were
cultured alone or together in 3% matrigel. Two days after plating, and every two days
thereafter, cells were treated with control media, media with ruxolitinib [100 nM],
media with SB505124 [2 µM], or media with ruxolitinib [100 nM] and SB505124 [2
µM]. The final concentration of DMSO in all experiments was 0.05%. Images were
acquired with a Leica DMI3000 inverted microscope outfitted with a DFC300 FX
camera. Fluorescence intensity was determined on three independent experiments
plated in duplicate using Image Pro Plus v.7 (Media Cybernetics).
5.14 Immunoblotting
5.14.1 Human
Immunoblotting was performed and lysates were prepared as described [114] using
CD31 (BD Biosciences), phosphorylated and total SMAD, phosphorylated JAK2
(p-JAK2), PARP (Cell Signaling Technology, Danvers, MA), and p-JAK1, JAK1,
JAK2 and ERK2 (gene: MAPK1) (Santa Cruz Biotechnology, Dallas, TX) antibodies.
Quantification of band area in each immunoblot was performed using ImageJ software
(http://imagej.nih.gov/ij/) from three independent experiments, and quantitation is
presented as mean ± SEM.
76
5.14.2 Mouse
ECs (200,000/well) were seeded in 6-well plates, serum-starved, and media was
replaced with control or CM containing SB505124 [2 µM], ruxolitinib [100 nM]
or DMSO [0.05%]. Lysates were prepared and immunoblotting was performed as
described [114]. For Stat3 knockdown, lysates were prepared from control- and
shRNA-transduced cells 48 hours post-seeding. p-SMAD2 (Cell Signaling), p-SMAD3
(Millipore), and SMAD2/3 (Cell Signaling) antibodies were used at dilutions of
1:1000. p-STAT3 and STAT3 antibodies were used at dilutions of 1:2000 and 1:1000,
respectively.
5.15 Mice
KRC and KPC mice were generated and maintained as described [114, 119]. For
intravital imaging, TRITC conjugated dextran (80 mg/kg) and hoescht (10 mg/kg)
were prepared in sterile saline, and injected into the tail vein of anesthetized KRC
mice. A lateral incision was made, and the pancreas was exposed and imaged using a
Leica TCS SP8 confocal microscope. Mice remained under anesthesia for the entire
experiment.
For therapeutic studies, 8 KRC mice or 8 KPC mice were randomized into ruxoli-
tinib (4 mice) or vehicle control (4 mice) groups at postnatal weeks 4 or 12, respectively.
For survival studies, 7 KRC mice were randomized into ruxolitinib (4 mice) or vehicle
control (3 mice) groups. Ruxolitinib (50 mg/kg) or equal volumes of vehicle (0.5%
hydroxypropyl methylcellulose (HPMC)) were administered to mice by daily gavage.
This dose is equivalent to or lower than doses used in other studies with this drug
[116, 172, 173]. All mice were genotyped twice (pre-weaning and post-necropsy). All
mouse studies were approved by the Institutional Care and Use Committee of Indiana
University. Log rank Kaplan-Meier survival analysis was used to test for significant
differences using Sigma Plot v.11.0 software (Systat Software).
5.16 Orthotopic model
KRC cells (200,000 cells) were injected into the pancreas of 28 (20 males, 8 females)
10-week-old syngeneic mice using KRC1017 and KRC1022-4 cells (10 males, 4 females
per cell line). On day 10, mice were randomized to vehicle and SB505124 treatment
groups (7 mice per group; 5 males and 2 females in each). Before treatment began,
tumors were imaged using Vevo2100 high-resolution ultrasound (VisualSonics). Mice
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were injected i.p. daily with vehicle (75% DMSO, 25% saline) or 10 mg/kg SB505124,
and 7 days later tumors were imaged. 3D abdominal scans were acquired on days 10
(pretreatment) and 17 (1 week after treatment), and tumor volumes were calculated
using Vevo2100 System software. Daily injections continued up to day 50, and mice
were sacrificed as they became moribund. All mouse studies were approved by the
Institutional Care and Use Committee of Indiana University.
Sigma Plot was used for log-rank survival analysis, and 1 mouse from the SB505124
group was censored from the survival analysis since it died on day 10, shortly after
the first injection.
5.17 KRC tumor microarrays
Agilent SurePrint G3 Mouse GE 8x60K whole mouse genome microarrays were
hybridized using total RNA from five 2 month-old or four 4 month-old KRC tumors
(Cy5-labeled), or five and four age- and sex-matched normal pancreata (Cy3-labeled),
respectively. Array analysis of KRC tumors was performed by Miltenyi Biotec. Briefly,
array intensity values were extracted, background corrected, LOWESS normalized,
quantile normalized, and log2 transformed. Unpaired t-tests with equal variance
were used to test log2-normalized data for significant differences. The FDR was
controlled by adjusting the P-values using the method of Benjamini and Hochberg
[174]. Differentially expressed genes were considered statistically significant using |FC|
>= 2, P < 0.01 for the GO analysis and FC >= 1.5, FDR < 0.05 otherwise. For
comparison to the human TCGA 79 out of 129 gene angiogenic signature (FC >= 1.5,
FDR < 0.05, Strong vs. Weak PDAC), 77 mouse homologs were used, resulting in 13
and 43 concordantly expressed genes (FC >= 1.5, FDR < 0.05) in the 2 month old or
4 month old KRC tumors as compared to age-matched normal pancreata.
5.18 KPC tumor microarrays
Agilent SurePrint G3 Mouse GE 8x60K whole mouse genome microarrays were
hybridized using total RNA from three 3 month-old tumors (Cy5-labeled), or three
age- and sex-matched normal pancreata (Cy3-labeled). Array analysis of KRC tumors
was performed by Miltenyi Biotec. Briefly, array intensity values were extracted,
background corrected, log2 transformed, LOESS normalized, and quantile normalized.
Unpaired t-tests with equal variance were used to test log2-normalized data for
significant differences. The FDR was controlled by adjusting the P-values using
the method of Benjamini and Hochberg [174]. Differentially expressed genes were
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considered statistically significant using FC >= 1.5, FDR < 0.05. For comparison to
the human TCGA 79 out of 129 gene angiogenic signature (FC >= 1.5, FDR < 0.05,
Strong vs. Weak PDAC), 77 mouse homologs were used, resulting in 0 concordantly
expressed genes (FC >= 1.5, FDR < 0.05) in the 3 month old KPC tumors as
compared to age-matched normal pancreata.
5.19 KRC and KC cell line microarrays
Agilent Whole Mouse Genome 4x44K Microarrays were hybridized using total
RNA from 3 different passages of 3 pooled KRC cell lines (3 hybridizations total)
(Cy5-labeled), or 3 different passages of 2 pooled KC cell lines (3 samples technically
replicated for a total of 6 hybridizations). Array analysis of KRC and KC cell lines
was performed by Miltenyi Biotec. Briefly, array intensity values were extracted,
background corrected, log2 transformed, LOESS normalized, and quantile normalized.
Unpaired t-tests with equal variance were used to test log2-normalized data for
significant differences. The FDR was controlled by adjusting the P-values (Ps) using
the method of Benjamini and Hochberg [174]. Differentially expressed genes were
considered statistically significant using |FC| >= 2, P < 0.01 for the GO analysis and
FC >= 1.5, FDR < 0.05 otherwise.
5.20 KRC tumor Gene Ontology (GO)
For each probeset on the array (55,681 probesets), gene annotation information, in-
cluding the Entrez Gene ID, RefSeq ID, or gene symbol if available, were used to identify
the associated Mouse Genome Informatics (MGI) ID
(http://www.informatics.jax.org/) or multiple MGI IDs in a few cases of ambiguity.
Matches were found for 34,531 probesets representing 25,806 unique MGI IDs.
For the 2 month tumors compared to 2 month WT pancreata, 3,535 differentially
expressed probesets were identified (|FC| >= 2, P < 0.01), and 2,550 of these had
a matching MGI ID (representing 2,419 unique MGI IDs). For the 4 month tumors
compared to 4 month WT pancreata, 6,641 differentially expressed probesets were
identified (|FC| >= 2, P < 0.01), and 5,003 of these had a matching MGI ID
(representing 4,432 unique MGI IDs).
For each time point, the final unique MGI ID gene list and the 25,806 MGI ID
background gene list were uploaded on the Database for Annotation, Visualization and
Integrated Discovery (DAVID) site (http://david.abcc.ncifcrf.gov/home.jsp, version
6.7) [175, 176], and an analysis was run using the MGI ID as the identifier. We then
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focused on the enriched GO terms [162] in the biological process FAT ontology (which
represents a subset of the more specific terms from the ontology). The visualization
tool in AmiGO (http://amigo.geneontology.org/visualize?mode=client amigo) was
used to generate the graphical GO graphs.
5.21 KRC vs. KC cell line GO
For each probeset on the array (41,174 probesets), gene annotation information,
including the Entrez Gene ID, RefSeq ID, or gene symbol if available, were used to
identify the associated MGI ID (http://www.informatics.jax.org/). Matches were
found for 34,640 probesets representing 21,247 unique MGI IDs.
For KRC cells compared to KC cells, 2,960 differentially expressed probesets
were identified (|FC| >= 2, P < 0.01), and 2,773 of these had a matching MGI ID
(representing 2,206 unique MGI IDs).
The 2,206 MGI ID gene list and the 21,247 MGI ID background gene list were
uploaded on the DAVID site (http://david.abcc.ncifcrf.gov/home.jsp, version 6.7)
[175, 176], and an analysis was run using the MGI ID as the identifier. We then
focused on the enriched GO terms [162] in the biological process FAT ontology (which
represents a subset of the more specific GO terms). The visualization tool in AmiGO
(http://amigo.geneontology.org/visualize?mode=client amigo) was used to generate
the graphical GO graphs.
5.22 Quantitative Polymerase Chain Reaction (qPCR)
qPCR was performed for the indicated mRNAs using Taqman gene expression
assays (Life Technologies) and cDNA prepared from total RNA as described [114,
117]. Actb and Rps6 served as the endogenous controls for cells and tumor tissues,
respectively.
5.23 Cell proliferation
Cell proliferation was assessed by MTT [177]. Briefly, ECs (5,000/well) were
seeded in 96-well plates, serum starved, and media was replaced with serum-free media
(control) or CM from KRC cells. For inhibitor studies, SB505124 [2 µM], ruxolitinib
[100 nM] or DMSO [0.05%] were added to control and CM. Stat3 knockdown was
performed as described [142] by transducing ECs with two shRNAs that target murine
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Stat3 [178] or a non-targeting shRNA control (Thermo Scientific). Proliferation was
assessed at 48 hours. The mean of control-treated cells was normalized to 100%, and
changes in proliferation were calculated as % control in three independent experiments.
5.24 Migration
Migration was assessed using a Boyden chamber assay. ECs (20,000) were seeded
in 8.0 µm cell culture inserts (BD Biosciences) in serum-free media, and placed into
24-well plates containing serum-free media, or CM. For inhibitors, SB505124 [2 µM],
ruxolitinib [100 nM] or DMSO [0.05%] were added to the inserts and wells. After
16 hours, cells were fixed in methanol and stained. The total number of cells that
migrated was counted.
5.25 Enzyme-linked immunosorbent assay (ELISA)
KRC cells were seeded in 6-well plates (200,000/well). After 24 hours, cells were
serum-starved overnight, and treated with control media or TGF-β1 (gene: Tgfb1)
[0.5 nM] for 24 hours. CM was prepared, and levels of the indicated cytokines
were determined using a Milliplex ELISA kit (Millipore) per the manufacturer’s
recommendation.
5.26 Luciferase assays
ECs (25,000) were seeded in 24-well culture plates. After 24 hours, ECs were
transfected with a STAT3 luciferase reporter (Promega), and Renilla to control for
transfection efficiency, using Lipofectamine 2000. After overnight serum starvation,
media was replaced with control media or CM for 24 hours, and luciferase assays were
performed on three independent experiments as described [114].
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6 Supplemental material
6.1 Supplemental tables
Table S1: Expression of 186 TGF-β responsive genes in Strong PDAC and PNET vs. Weak PDAC
Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
25841 ABTB2 -1.50 0.001686 0.008159 -8.76 6.63E-13 3.06E-11
23205 ACSBG1 1.23 1 1 24.25 0.175672 0.337868
53616 ADAM22 7.97 3.42E-13 3.01E-11 3.78 0.000637 0.003431
9590 AKAP12 3.79 1.37E-10 5.31E-09 1.62 0.198132 0.368052
286 ANK1 -2.98 0.000112 0.000807 1.22 0.660044 0.812612
23141 ANKLE2 -1.24 0.0763 0.183431 1.13 0.631461 0.790037
94134 ARHGAP12 -1.20 0.180306 0.35276 -1.92 0.006344 0.02383
467 ATF3 -1.16 0.280025 0.485873 -2.58 0.02225 0.066527
54880 BCOR 1.00 0.925665 1 1.70 0.007745 0.028063
8553 BHLHE40 -1.44 0.001574 0.007694 -3.61 5.50E-08 8.81E-07
635 BHMT -1.27 0.674828 0.850796 1.58 0.677618 0.826618
659 BMPR2 1.93 1.26E-05 0.000121 -1.06 0.710588 0.852558
676 BRDT 3.41 1 1 -2.19 1 1
28984 C13orf15 1.56 0.02266 0.069772 1.90 0.019646 0.060253
126353 C19orf21 -3.93 2.34E-17 7.37E-15 -6.85 9.82E-10 2.30E-08
27042 C1orf107 -1.05 0.693799 0.857321 -2.17 0.001376 0.006637
81626 C1orf14 1.78 1 1 -Inf 1 1
221749 C6orf145 1.13 0.483499 0.704075 -2.07 0.001577 0.007445
203197 C9orf91 1.53 0.006379 0.024712 1.78 0.014934 0.04824
65981 CAPRIN2 -2.34 0.000191 0.001277 -1.61 0.25224 0.438729
838 CASP5 1.26 0.770198 0.901502 -5.72 0.374824 0.58161
79780 CCDC82 1.14 0.518067 0.737443 -1.22 0.480953 0.684663
54520 CCDC93 1.15 0.355736 0.573358 1.34 0.1724 0.332867
9332 CD163 5.32 3.03E-11 1.42E-09 -1.99 0.037955 0.102589
913 CD1E 3.58 9.66E-05 0.000714 -2.72 0.024562 0.072198
10849 CD3EAP -1.01 0.766337 0.899805 -1.30 0.255079 0.441977
5128 CDK17 1.68 0.001242 0.006311 1.42 0.09233 0.207009
55602 CDKN2AIP -1.26 0.089821 0.208515 1.10 0.696386 0.841997
1030 CDKN2B 1.82 0.013022 0.044207 -3.29 0.000765 0.004013
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
50515 CHST11 1.82 0.001907 0.009035 -1.76 0.01087 0.037173
9469 CHST3 1.90 0.000113 0.000811 -1.02 0.710898 0.852776
1160 CKMT2 1.08 0.683904 0.853518 -3.48 0.0181 0.056383
23529 CLCF1 -1.42 0.009147 0.033102 -18.01 1.68E-18 1.96E-16
1307 COL16A1 1.39 0.044775 0.120671 -2.57 0.000189 0.001196
1410 CRYAB 1.57 0.27534 0.480768 3.35 0.038759 0.104317
1436 CSF1R 3.09 2.65E-13 2.47E-11 -1.23 0.247224 0.432026
1454 CSNK1E -1.38 0.011202 0.039043 -1.04 0.835104 0.947254
1474 CST6 -1.35 0.247021 0.445257 -116.94 8.77E-08 1.33E-06
1490 CTGF 3.33 1.11E-07 1.86E-06 1.03 0.862929 0.967639
1591 CYP24A1 1.09 1 1 -100.23 0.008872 0.031411
56603 CYP26B1 2.77 8.09E-05 0.000614 2.33 0.016291 0.05174
1573 CYP2J2 -2.24 2.89E-06 3.28E-05 -6.82 1.27E-08 2.36E-07
9267 CYTH1 -1.05 0.354144 0.571534 -2.02 0.003228 0.013609
51339 DACT1 2.63 4.39E-09 1.10E-07 -2.28 0.00157 0.007418
1644 DDC -1.90 0.396732 0.61618 15.03 0.002554 0.011166
25786 DGCR11 -1.14 0.652232 0.839763 -1.74 0.313331 0.512871
10395 DLC1 3.17 6.90E-14 7.65E-12 2.19 0.000228 0.001405
23333 DPY19L1 1.03 1 1 -1.94 0.003275 0.013794
8445 DYRK2 1.28 0.092332 0.212974 -1.09 0.658264 0.811179
1906 EDN1 1.12 0.467069 0.68813 -4.87 3.04E-07 4.03E-06
22936 ELL2 1.79 4.12E-06 4.50E-05 7.23 6.82E-24 2.01E-21
2043 EPHA4 1.03 0.812846 0.929315 1.48 0.217778 0.394668
2114 ETS2 1.10 0.687442 0.85424 -2.05 0.000467 0.002634
2150 F2RL1 -1.65 0.00474 0.01931 -8.60 1.88E-10 5.23E-09
79633 FAT4 5.32 1.58E-20 1.25E-17 2.02 0.007414 0.027068
10979 FERMT2 3.11 1.15E-13 1.17E-11 1.29 0.235036 0.416798
2244 FGB -1.41 0.724069 0.873385 116.69 0.098781 0.217665
2246 FGF1 1.91 0.194811 0.374355 12.11 4.87E-05 0.000365
54874 FNBP1L 1.10 0.463622 0.684982 1.20 0.381186 0.588152
2297 FOXD1 -2.96 7.67E-05 0.000585 -21.06 6.94E-06 6.49E-05
2295 FOXF2 1.21 0.462769 0.684307 -2.33 0.005274 0.020498
51343 FZR1 -1.78 8.28E-06 8.38E-05 1.28 0.310171 0.509018
4616 GADD45B 1.31 0.244027 0.441464 1.16 0.383587 0.590564
8843 GPR109B 2.24 0.063272 0.15848 -5.38 0.008142 0.029254
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
3142 HLX 1.21 0.418067 0.638368 -1.25 0.273136 0.463779
3269 HRH1 -1.23 0.078402 0.18734 -4.27 4.77E-08 7.75E-07
9956 HS3ST2 1.95 0.240568 0.43662 -5.09 0.059959 0.147315
3352 HTR1D -1.06 0.843386 0.949958 -5.50 0.000507 0.002821
3373 HYAL1 -2.82 3.10E-06 3.49E-05 -9.79 1.29E-06 1.45E-05
3399 ID3 1.03 0.898439 0.986619 -1.06 0.584586 0.752716
3589 IL11 1.87 0.48517 0.705724 -4.52 0.219862 0.397423
29949 IL19 -2.29 0.346467 0.563436 -Inf 0.235528 0.417483
9173 IL1RL1 3.88 0.004441 0.01831 1.97 0.26266 0.45084
3667 IRS1 1.30 0.164925 0.330817 -1.55 0.018936 0.058514
3678 ITGA5 1.88 0.00143 0.007113 -1.76 0.025214 0.073721
3694 ITGB6 -1.20 0.196205 0.376223 -156.01 5.74E-19 7.26E-17
58494 JAM2 2.83 2.32E-08 4.76E-07 1.24 0.307727 0.505975
221037 JMJD1C 1.57 0.003792 0.016096 -1.08 0.663027 0.814641
23210 JMJD6 -1.20 0.141488 0.29553 1.21 0.471906 0.676124
3725 JUN -1.11 0.230011 0.423357 -1.66 0.010102 0.034982
3726 JUNB -1.75 1.27E-06 1.61E-05 -1.67 0.010997 0.037534
23189 KANK1 1.52 0.013635 0.045944 3.10 3.24E-06 3.28E-05
3783 KCNN4 -3.25 4.45E-15 7.31E-13 -163.87 3.09E-33 3.05E-30
23135 KDM6B 1.21 0.263495 0.46611 1.85 0.005399 0.020896
80759 KHDC1 -1.36 0.302388 0.512847 2.34 0.068656 0.164048
7071 KLF10 1.51 0.008035 0.029789 1.09 0.599354 0.765094
9314 KLF4 -1.66 0.000337 0.002085 -3.89 2.54E-06 2.64E-05
8609 KLF7 2.08 0.000897 0.004785 -1.32 0.200868 0.371979
55323 LARP6 1.09 0.671374 0.849771 1.29 0.355642 0.560123
23592 LEMD3 1.34 0.040008 0.110186 1.27 0.257506 0.444505
3976 LIF -1.36 0.041359 0.113 -3.12 7.30E-05 0.000522
9388 LIPG 1.82 0.001285 0.006494 -2.10 0.003518 0.014642
29995 LMCD1 1.73 0.001973 0.009297 -1.03 0.801165 0.921573
29967 LRP12 3.39 3.32E-12 2.14E-10 3.33 4.17E-07 5.30E-06
4053 LTBP2 3.07 6.28E-14 7.21E-12 -1.12 0.383343 0.590308
4054 LTBP3 1.12 0.530327 0.747979 1.51 0.038431 0.103591
116372 LYPD1 1.03 0.866997 0.965274 -3.04 0.014884 0.048133
9935 MAFB 2.69 0.008175 0.030182 17.59 1.58E-08 2.86E-07
4216 MAP3K4 1.42 0.014183 0.047443 1.87 0.003287 0.01383
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
4142 MAS1 1.42 1 1 129.46 0.241457 0.425281
4146 MATN1 1.22 0.978986 1 2.00 0.557309 0.732503
54797 MED18 -1.22 0.335781 0.552403 -1.34 0.375345 0.582188
57591 MKL1 1.06 0.967787 1 -1.60 0.046285 0.120024
22877 MLXIP 1.65 0.000496 0.002906 1.89 0.002791 0.01205
23531 MMD 1.87 9.99E-05 0.000734 1.05 0.880584 0.979094
10205 MPZL2 -1.15 0.368703 0.586358 -12.34 4.50E-12 1.73E-10
9617 MTRF1 -1.38 0.067629 0.167219 -1.27 0.400481 0.606918
4606 MYBPC2 3.79 0.152071 0.311643 -7.54 0.246888 0.43161
9612 NCOR2 -1.17 0.132268 0.280335 1.73 0.011355 0.03845
3340 NDST1 1.87 2.48E-06 2.88E-05 3.53 4.37E-11 1.39E-09
4776 NFATC4 1.04 0.859542 0.959934 1.66 0.168547 0.326941
4803 NGF 1.62 0.27086 0.475285 1.04 0.722244 0.861361
4908 NTF3 1.15 0.882171 0.97594 -1.29 0.852683 0.960022
58495 OVOL2 -3.37 1.75E-12 1.22E-10 -2.35 0.01552 0.049757
400961 PAIP2B -1.41 0.761897 0.897157 3.31 0.0123 0.04122
5154 PDGFA -1.67 0.0003 0.001883 -1.31 0.568087 0.739334
5155 PDGFB 1.05 1 1 -1.25 0.25153 0.437865
8572 PDLIM4 -1.04 0.592905 0.797824 1.81 0.134812 0.276712
5209 PFKFB3 1.14 0.837375 0.946192 -1.26 0.279043 0.471457
9767 PHF16 1.15 0.320814 0.535408 -1.10 0.903682 0.995004
23187 PHLDB1 1.51 0.004391 0.018137 -1.88 0.003485 0.014525
5293 PIK3CD 2.81 1.21E-08 2.66E-07 -1.66 0.040039 0.107091
5569 PKIA 1.80 0.007294 0.027533 2.28 0.006303 0.023725
59338 PLEKHA1 -1.13 0.373285 0.591042 -1.27 0.276309 0.467919
56937 PMEPA1 -1.15 0.274573 0.479725 -9.24 6.06E-13 2.83E-11
5376 PMP22 2.19 0.000293 0.001847 -1.47 0.182326 0.347239
5467 PPARD -1.02 0.628708 0.824119 -2.12 0.00119 0.00587
10848 PPP1R13L -2.53 1.42E-10 5.51E-09 -5.89 2.83E-09 6.02E-08
5521 PPP2R2B 2.29 0.001532 0.007525 13.74 9.09E-13 4.06E-11
5553 PRG2 -1.68 0.299683 0.509526 -2.08 0.496087 0.69676
79037 PVRIG 2.06 0.095408 0.218622 1.47 0.456456 0.661672
9693 RAPGEF2 1.43 0.015956 0.052179 1.43 0.124769 0.260478
23186 RCOR1 -1.24 0.112413 0.247689 -1.06 0.742573 0.876287
8786 RGS11 -1.46 0.199496 0.380632 6.38 1.66E-05 0.00014
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
85
Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
6002 RGS12 -1.94 2.18E-07 3.35E-06 1.20 0.625767 0.786101
388 RHOB -1.32 0.005838 0.022959 -1.56 0.019829 0.060644
6038 RNASE4 -1.58 0.033794 0.096078 1.73 0.072076 0.170564
376412 RNF126P1 -1.94 0.404669 0.624551 -2.36 0.86816 0.970968
127544 RNF19B 1.01 0.818081 0.932219 -1.18 0.437159 0.643217
6236 RRAD 1.16 0.998934 1 -2.56 0.650931 0.805719
9853 RUSC2 1.11 0.73376 0.879502 1.35 0.41221 0.618671
6274 S100A3 -1.57 0.045352 0.121858 -5.19 0.000364 0.002116
29970 SCHIP1 1.64 0.00758 0.028386 2.28 0.001727 0.008049
23541 SEC14L2 -1.30 0.08198 0.193917 -3.12 0.00024 0.001468
6446 SGK1 2.19 1.45E-08 3.12E-07 -1.82 0.022461 0.067054
8631 SKAP1 -2.36 0.155027 0.316038 3.29 0.103478 0.225697
6498 SKIL 1.99 4.10E-05 0.000338 -3.04 3.11E-06 3.17E-05
10786 SLC17A3 -1.22 0.770785 0.901891 3.82 0.482116 0.685895
1836 SLC26A2 2.44 3.83E-09 9.75E-08 2.37 5.86E-05 0.000428
9057 SLC7A6 1.47 0.01728 0.055779 -1.17 0.51088 0.707316
6578 SLCO2A1 1.53 0.025653 0.076978 1.14 0.625347 0.785874
4091 SMAD6 -2.33 1.92E-07 3.01E-06 -2.97 0.000274 0.001651
54498 SMOX -2.24 2.85E-08 5.68E-07 -3.86 1.03E-07 1.53E-06
6525 SMTN 1.26 0.710213 0.866357 -2.09 0.315032 0.514662
57154 SMURF1 -1.50 0.000728 0.004008 -1.87 0.014587 0.047364
64750 SMURF2 1.56 0.005722 0.02259 -1.12 0.641038 0.797712
6615 SNAI1 2.11 5.14E-05 0.000412 -1.92 0.016928 0.05343
9306 SOCS6 1.34 0.057184 0.146596 1.66 0.03024 0.085499
8877 SPHK1 -1.35 0.053592 0.139147 -5.92 9.06E-08 1.36E-06
80176 SPSB1 1.73 0.000173 0.001177 -1.81 0.00912 0.032157
23648 SSBP3 -1.32 0.062633 0.157215 1.20 0.185921 0.351489
6781 STC1 2.20 9.74E-07 1.26E-05 2.02 0.003392 0.0142
6862 T -3.83 0.419899 0.64036 -2.70 1 1
6876 TAGLN 1.83 0.012635 0.043109 -2.38 0.021745 0.065283
23102 TBC1D2B 1.60 0.001821 0.008694 -1.19 0.411877 0.618354
9519 TBPL1 1.08 0.560233 0.772924 1.46 0.109594 0.235857
6926 TBX3 1.90 0.000278 0.001766 1.91 0.040844 0.108845
7942 TFEB -1.17 0.203398 0.386332 1.35 0.244926 0.429114
7066 THPO -1.09 1 1 -5.55 0.12764 0.265208
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
PNET
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
7090 TLE3 -1.18 0.138481 0.290477 -1.25 0.504674 0.703056
79905 TMC7 -2.69 6.89E-11 2.90E-09 -22.60 5.03E-20 7.63E-18
25816 TNFAIP8 1.55 0.012616 0.043051 -6.96 1.44E-11 4.98E-10
84951 TNS4 -1.83 0.010356 0.03666
-
2250.70 7.26E-16 5.78E-14
10221 TRIB1 -1.10 0.277087 0.482704 -2.46 0.000124 0.000823
10382 TUBB4 -1.28 0.283641 0.49036 -1.37 0.392716 0.599197
56995 TULP4 1.39 0.026084 0.077982 1.70 0.019603 0.06014
5412 UBL3 1.36 0.020416 0.064146 2.59 7.10E-06 6.61E-05
7481 WNT11 -2.26 0.047416 0.126231 -6.39 0.077876 0.18138
51384 WNT16 -1.76 0.225762 0.417354 -1.34 0.782576 0.907168
7473 WNT3 -1.02 0.931365 1 1.19 0.821232 0.937107
54361 WNT4 1.24 0.589148 0.794771 30.49 6.42E-07 7.81E-06
7476 WNT7A -2.30 0.000805 0.004364 -94.33 1.26E-11 4.41E-10
81555 YIPF5 1.35 0.024842 0.074982 1.22 0.352082 0.556469
23174 ZCCHC14 1.10 0.562568 0.774584 1.05 0.763676 0.892619
677 ZFP36L1 1.33 0.083793 0.197238 -4.82 5.16E-11 1.62E-09
55279 ZNF654 1.35 0.103117 0.231715 -1.03 0.90664 0.997089
PDAC: Pancreatic ductal adenocarcinoma; PNET: Pancreatic neuroendocrine tumor; FDR:
False Discovery Rate; 15 genes up-regulated in both Strong PDAC and PNET vs. Weak PDAC;
50 genes up-regulated in Strong PDAC vs. Weak PDAC; 25 genes up-regulated in PNET vs.
Weak PDAC; Differential expression cut off: Fold Change >= 1.5, FDR < 0.05
Table S2: Expression of 85 positive regulators of inflammation in Strong PDAC vs. Weak PDAC
Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
101 ADAM8 -2.18 1.25E-07 2.07E-06
136 ADORA2B -1.40 0.327524 0.543411
140 ADORA3 2.78 4.72E-08 8.75E-07
185 AGTR1 2.35 0.000345 0.002126
338699 ANKRD42 1.02 0.898732 0.986776
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 28 genes up-regulated in Strong PDAC vs.
Weak PDAC; 35 genes differentially expressed in Strong
PDAC vs. Weak PDAC (28 up-regulated, 7 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
87
Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
6369 CCL24 -6.02 0.265392 0.468215
6348 CCL3 1.78 0.037072 0.103521
1236 CCR7 8.60 0.004296 0.017835
100133941 CD24 -1.23 0.345747 0.562815
940 CD28 8.26 3.22E-11 1.50E-09
961 CD47 1.03 0.832139 0.942403
9575 CLOCK 2.16 1.01E-05 9.99E-05
1268 CNR1 5.38 1.65E-10 6.31E-09
84699 CREB3L3 -2.87 0.401734 0.621051
1520 CTSS 1.11 0.57403 0.783145
6376 CX3CL1 -1.13 0.395828 0.615206
1909 EDNRA 2.53 4.40E-09 1.10E-07
1956 EGFR 1.70 0.00155 0.007595
2161 F12 -6.21 3.35E-15 5.68E-13
2167 FABP4 3.31 0.034416 0.097503
2205 FCER1A 2.66 0.000966 0.005082
2207 FCER1G 1.89 0.000282 0.001785
2867 FFAR2 -1.97 0.450042 0.671311
2865 FFAR3 1.32 0.561418 0.773537
51704 GPRC5B 1.04 0.893443 0.983375
8692 HYAL2 1.21 0.194683 0.374217
3620 IDO1 2.81 0.239865 0.435599
3593 IL12B 3.16 0.334213 0.550746
3600 IL15 1.13 0.696756 0.858676
3605 IL17A 9.42 1 1
27190 IL17B 1.30 0.919437 1
27189 IL17C -4.67 0.044896 0.120851
112744 IL17F -2.45 0.649887 0.838644
23765 IL17RA 1.29 0.173192 0.342351
84818 IL17RC -1.77 2.58E-05 0.000226
3606 IL18 -1.24 0.092931 0.214054
9173 IL1RL1 3.88 0.004441 0.01831
3558 IL2 2.88 0.772575 0.902868
59067 IL21 Inf 1 1
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 28 genes up-regulated in Strong PDAC vs.
Weak PDAC; 35 genes differentially expressed in Strong
PDAC vs. Weak PDAC (28 up-regulated, 7 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
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Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
51561 IL23A -1.46 0.107447 0.239118
90865 IL33 5.12 1.03E-12 7.78E-11
3569 IL6 4.06 0.008857 0.032238
3572 IL6ST 5.81 9.39E-20 5.49E-17
3673 ITGA2 1.34 0.099583 0.226062
3717 JAK2 1.59 0.008254 0.030425
3818 KLKB1 1.00 0.974636 1
3929 LBP 2.91 0.19577 0.375759
4049 LTA 4.90 0.001887 0.008958
5603 MAPK13 -1.56 0.006447 0.024891
91662 NLRP12 2.60 0.072132 0.175901
4889 NPY5R 1.24 0.701563 0.861658
5008 OSM 1.37 0.371834 0.589543
9180 OSMR 2.27 4.31E-07 6.15E-06
5138 PDE2A 2.81 7.58E-10 2.44E-08
5320 PLA2G2A 1.30 1 1
7941 PLA2G7 2.47 0.021131 0.065952
5733 PTGER3 3.79 3.96E-13 3.43E-11
5734 PTGER4 1.64 0.000637 0.003575
5743 PTGS2 1.47 0.55703 0.770377
6223 RPS19 -2.16 1.32E-07 2.15E-06
6283 S100A12 3.55 0.083594 0.196844
6279 S100A8 -1.00 0.698008 0.85942
6280 S100A9 -1.02 0.764485 0.898862
5054 SERPINE1 3.65 7.38E-07 9.88E-06
8723 SNX4 1.06 0.726897 0.875185
6776 STAT5A 1.13 0.59753 0.801278
6777 STAT5B 1.42 0.022094 0.06837
6863 TAC1 -1.45 0.383751 0.603045
7052 TGM2 1.48 0.099061 0.225149
81793 TLR10 9.80 5.76E-05 0.000455
7097 TLR2 1.83 0.000326 0.002029
7098 TLR3 1.37 0.107796 0.239626
7099 TLR4 3.10 3.33E-11 1.55E-09
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 28 genes up-regulated in Strong PDAC vs.
Weak PDAC; 35 genes differentially expressed in Strong
PDAC vs. Weak PDAC (28 up-regulated, 7 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
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Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
51284 TLR7 4.61 1.05E-11 5.77E-10
54106 TLR9 1.93 0.056105 0.14437
7124 TNF -1.04 0.568062 0.778033
8792 TNFRSF11A -1.41 0.168751 0.336384
7132 TNFRSF1A -1.11 0.349323 0.565869
8600 TNFSF11 -1.59 0.093752 0.215598
7292 TNFSF4 2.06 0.002548 0.011533
10318 TNIP1 -1.28 0.055041 0.142091
6845 VAMP7 1.65 0.000551 0.003168
8673 VAMP8 -2.01 3.11E-07 4.58E-06
7474 WNT5A 1.77 0.00685 0.026145
7784 ZP3 -2.28 1.80E-05 0.000165
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 28 genes up-regulated in Strong PDAC vs.
Weak PDAC; 35 genes differentially expressed in Strong
PDAC vs. Weak PDAC (28 up-regulated, 7 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
Table S3: Expression of 81 negative regulators of inflammation in Strong PDAC vs. Weak PDAC
Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
29 ABR -1.02 0.827246 0.938538
54 ACP5 1.29 0.613756 0.813698
100 ADA 1.16 0.487718 0.708096
116 ADCYAP1 3.88 0.001388 0.006933
9370 ADIPOQ 10.99 0.003206 0.013933
134 ADORA1 -1.44 0.347902 0.56478
325 APCS 1.03 0.807491 0.925483
335 APOA1 1.02 1 1
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 17 genes down-regulated in Strong PDAC vs.
Weak PDAC; 33 genes differentially expressed in Strong
PDAC vs. Weak PDAC (16 up-regulated, 17 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
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Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
348 APOE 1.18 0.912798 0.99624
55870 ASH1L 1.38 0.022006 0.068192
613 BCR -1.51 0.001573 0.007693
114899 C1QTNF3 2.14 0.020014 0.063193
80381 CD276 1.07 0.822491 0.93528
66005 CHID1 -1.45 0.077573 0.185794
1269 CNR2 26.26 0.000343 0.002114
11221 DUSP10 -1.32 0.116857 0.255058
1991 ELANE -1.02 0.767792 0.900335
90268 FAM105B 1.16 0.368931 0.586627
388581 FAM132A -3.37 3.10E-05 0.000265
55527 FEM1A -1.03 1 1
2294 FOXF1 2.12 0.000595 0.003377
50943 FOXP3 4.20 1.38E-06 1.73E-05
2625 GATA3 1.50 0.328561 0.544631
2629 GBA -1.17 0.335523 0.55207
2693 GHSR 4.83 0.371577 0.589423
2852 GPER -1.54 0.580602 0.788616
338557 GPR120 -4.11 0.028049 0.082564
2876 GPX1 -1.61 0.000157 0.001084
2877 GPX2 -3.32 9.25E-08 1.60E-06
2950 GSTP1 -2.32 5.91E-11 2.53E-09
3123 HLA-DRB1 2.08 0.000373 0.00227
8870 IER3 -2.53 7.66E-08 1.34E-06
3586 IL10 3.03 0.035074 0.099084
3593 IL12B 3.16 0.334213 0.550746
3558 IL2 2.88 0.772575 0.902868
53833 IL20RB -1.47 0.330891 0.547291
116379 IL22RA2 1.01 0.799682 0.920372
3559 IL2RA 3.84 3.93E-08 7.47E-07
3565 IL4 1.45 0.97783 1
3630 INS 1.18 0.794523 0.917077
9314 KLF4 -1.66 0.000337 0.002085
3848 KRT1 4.36 0.072277 0.176083
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 17 genes down-regulated in Strong PDAC vs.
Weak PDAC; 33 genes differentially expressed in Strong
PDAC vs. Weak PDAC (16 up-regulated, 17 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
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Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
5598 MAPK7 -1.03 0.579672 0.787785
4210 MEFV 3.99 0.003634 0.015501
284207 METRNL -1.50 0.000295 0.001854
4598 MVK -1.87 9.38E-05 0.000697
80762 NDFIP1 1.00 0.721453 0.872355
4790 NFKB1 1.28 0.093579 0.215251
91662 NLRP12 2.60 0.072132 0.175901
114548 NLRP3 3.99 6.42E-09 1.53E-07
79671 NLRX1 -1.24 0.11242 0.247689
64127 NOD2 1.23 0.601968 0.804244
10062 NR1H3 -1.55 0.000785 0.004272
4907 NT5E -1.10 0.745993 0.886751
55872 PBK -1.54 0.036326 0.10184
8993 PGLYRP1 1.68 0.967955 1
5467 PPARD -1.02 0.628708 0.824119
5468 PPARG -2.82 1.00E-08 2.26E-07
5580 PRKCD -1.52 0.000383 0.00232
5692 PSMB4 -1.64 0.000331 0.002054
5734 PTGER4 1.64 0.000637 0.003575
5740 PTGIS 2.51 0.032953 0.094137
5771 PTPN2 -1.08 0.566503 0.777092
27342 RABGEF1 1.06 0.659667 0.843973
6223 RPS19 -2.16 1.32E-07 2.15E-06
6288 SAA1 1.56 0.332259 0.548654
55829 SELS -1.44 0.010148 0.036066
462 SERPINC1 -5.45 0.002483 0.011294
5176 SERPINF1 2.70 3.37E-10 1.17E-08
81858 SHARPIN -1.92 2.10E-06 2.50E-05
4088 SMAD3 -1.65 1.94E-05 0.000176
9021 SOCS3 1.73 0.004227 0.017615
6693 SPN 3.36 3.34E-10 1.17E-08
7032 TFF2 -1.85 0.215818 0.404138
7128 TNFAIP3 2.69 2.90E-09 7.66E-08
79626 TNFAIP8L2 2.12 0.001088 0.005629
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 17 genes down-regulated in Strong PDAC vs.
Weak PDAC; 33 genes differentially expressed in Strong
PDAC vs. Weak PDAC (16 up-regulated, 17 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
92
Entrez
Gene
ID
Gene Symbol
Strong PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
7132 TNFRSF1A -1.11 0.349323 0.565869
7133 TNFRSF1B 1.84 0.000111 0.0008
7301 TYRO3 -1.32 0.167036 0.333937
55075 UACA 1.31 0.091579 0.211729
7538 ZFP36 1.06 0.780563 0.908267
PDAC: Pancreatic ductal adenocarcinoma; FDR: False
Discovery Rate; 17 genes down-regulated in Strong PDAC vs.
Weak PDAC; 33 genes differentially expressed in Strong
PDAC vs. Weak PDAC (16 up-regulated, 17 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR <
0.05
Table S4: Expression of 45 JAK/STAT signaling pathway genes in Strong and Moderate PDAC vs.
Weak PDAC
Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
Moderate PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
10000 AKT3 3.42 7.12E-15 1.05E-12 2.09 2.91E-07 8.88E-05
867 CBL 1.66 0.003123 0.013644 1.32 0.123839 0.451204
23624 CBLC -4.26 7.19E-25 2.04E-21 -1.68 6.96E-05 0.004001
1271 CNTFR 1.56 0.664617 0.847142 -4.02 0.001979 0.037008
1438 CSF2RA 2.36 1.49E-05 0.00014 1.28 0.258325 0.660969
1439 CSF2RB 4.98 2.82E-07 4.21E-06 1.96 0.025106 0.181024
1441 CSF3R 2.68 0.000418 0.002506 1.73 0.056468 0.29521
2033 EP300 1.64 0.00059 0.003353 1.32 0.049323 0.272434
2057 EPOR -1.51 0.011135 0.038858 -1.16 0.264323 0.669341
2690 GHR 4.99 8.99E-06 9.01E-05 1.75 0.047669 0.267402
338376 IFNE -7.53 0.002234 0.010338 -1.85 0.279327 0.6884
3459 IFNGR1 1.56 0.002345 0.010776 1.26 0.098858 0.399409
3587 IL10RA 3.23 7.52E-11 3.12E-09 1.33 0.119316 0.442423
3594 IL12RB1 1.91 0.014321 0.047841 1.09 0.695597 0.934695
50615 IL21R 3.43 1.10E-05 0.000108 1.66 0.053024 0.285062
3559 IL2RA 3.84 3.93E-08 7.47E-07 1.88 0.012143 0.115874
PDAC: Pancreatic ductal adenocarcinoma; FDR: False Discovery Rate; 44 differentially
expressed genes in Strong PDAC vs. Weak PDAC (40 up-regulated, 4 down-regulated); 10
differentially expressed in Moderate PDAC vs. Weak PDAC (8 up-regulated, 2 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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Entrez
Gene
ID
Gene
Symbol
Strong PDAC
vs.
Weak PDAC
Moderate PDAC
vs.
Weak PDAC
Fold
Change
P-value FDR
Fold
Change
P-value FDR
3560 IL2RB 3.42 4.88E-09 1.19E-07 1.54 0.021141 0.163487
3561 IL2RG -1.73 0.004305 0.017862 -1.48 0.048387 0.269966
3563 IL3RA 1.58 0.007286 0.027509 1.09 0.525521 0.891302
3569 IL6 4.06 0.008857 0.032238 1.01 0.817692 0.983347
3570 IL6R 2.86 6.32E-05 0.000494 1.41 0.163812 0.526778
3572 IL6ST 5.81 9.39E-20 5.49E-17 2.43 3.26E-07 9.02E-05
3575 IL7R 9.98 9.41E-18 3.66E-15 2.54 0.000195 0.008046
3716 JAK1 1.72 0.000154 0.001067 1.32 0.038427 0.233472
3717 JAK2 1.59 0.008254 0.030425 -1.03 0.649789 0.918528
3718 JAK3 2.25 0.000455 0.002697 1.25 0.353542 0.764938
3952 LEP 7.28 0.014287 0.047744 -2.01 0.381413 0.78991
3953 LEPR 3.87 1.75E-09 4.95E-08 1.86 0.001661 0.033534
3977 LIFR 2.30 2.48E-06 2.87E-05 -1.09 0.715637 0.943575
9180 OSMR 2.27 4.31E-07 6.15E-06 1.86 9.51E-05 0.005001
9063 PIAS2 1.95 0.000441 0.002626 1.23 0.23986 0.638306
5290 PIK3CA 2.24 1.89E-06 2.27E-05 1.65 0.002061 0.037797
5293 PIK3CD 2.81 1.21E-08 2.66E-07 1.60 0.00454 0.062265
5294 PIK3CG 5.16 1.46E-12 1.06E-10 1.96 0.0031 0.049477
5295 PIK3R1 2.41 1.71E-09 4.83E-08 1.41 0.006457 0.076798
8503 PIK3R3 1.79 0.000155 0.001073 1.16 0.293415 0.705203
23533 PIK3R5 3.91 7.50E-13 5.93E-11 1.68 0.003025 0.048665
8835 SOCS2 1.90 5.22E-05 0.000418 -1.03 0.863102 1
9021 SOCS3 1.73 0.004227 0.017615 1.13 0.607341 0.909456
9655 SOCS5 1.82 0.00014 0.00098 1.39 0.02991 0.202197
30837 SOCS7 1.91 0.011688 0.040439 1.39 0.132412 0.467962
6655 SOS2 1.58 0.001599 0.007794 1.29 0.053097 0.285225
10252 SPRY1 2.23 4.05E-08 7.65E-07 1.30 0.040648 0.242245
6772 STAT1 1.56 0.012906 0.043866 1.36 0.068442 0.327722
6775 STAT4 3.22 1.17E-07 1.96E-06 1.21 0.233588 0.631481
PDAC: Pancreatic ductal adenocarcinoma; FDR: False Discovery Rate; 44 differentially
expressed genes in Strong PDAC vs. Weak PDAC (40 up-regulated, 4 down-regulated); 10
differentially expressed in Moderate PDAC vs. Weak PDAC (8 up-regulated, 2 down-regulated);
Differential expression cut off: |Fold Change| >= 1.5, FDR < 0.05
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6.2 Supplemental figures
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Figure S1: Human PDAC (hPDAC) tissue with strong CD31 (gene: PECAM1) im-
munoreactivity. (A-O) 28% (15/54) of PDAC tissues had strong CD31 immunoreactivity.
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Figure S2: hPDAC tissue with moderate CD31 immunoreactivity. (A-T) 37% (20/54) of
PDAC tissues had moderate CD31 immunoreactivity.
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Figure S3: hPDAC tissue with weak CD31 immunoreactivity. (A-S) 35% (19/54) of PDAC
tissues had weak CD31 immunoreactivity.
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